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ABSTRACT 
 
 Neuroblastoma is the most common pediatric cancer in infants, arising from the 
sympathoadrenal lineage of the neural crest.  Despite recent advances in other pediatric 
cancers, long term survival in high risk cases of neuroblastoma remains below 40%.  
Therefore, to develop successful therapeutics targeting high risk tumors, further research 
into the mechanisms involved in high risk tumor formation is necessary.  Prognosis in 
neuroblastoma is determined by a number of factors, including certain genetic and 
biological variables.  The genetic variable correlated most with high risk disease is 
amplification of the MYCN gene, which is present in ~25% of tumors.  Additionally, 
~70% of these MYCN-amplified tumors express the neurotrophin receptor TrkB, and its 
ligand, brain-derived neurotrophic factor (BDNF), with concurrent expression of these 
proteins correlated with high risk disease independent of MYCN-amplification status.  To 
better understand factors influencing MYCN-amplified tumor cell phenotype, and the role 
of TrkB signaling in high risk neuroblastoma, the experiments in this dissertation 
examined growth factor effects on MYCN-amplified tumor cells from the TH-MYCN 
mouse model of neuroblastoma, as well as the creation, and expression of a constitutively 
active TrkB receptor in a neural crest derived cell line.  
 Overexpression of MYCN targeted to the sympathoadrenal lineage by the 
tyrosine hydroxylase (TH) promoter is sufficient to cause neuroblastoma in 100% of mice 
homozygous for the transgene (TH-MYCN mice).  Screening growth factors, in vitro 
treatment of tumor cells from dissociated TH-MYCN tumors with ciliary neurotrophic 
factor (CNTF) was found to promote differentiation marked by increased neurite 
outgrowth, and withdrawal of actively dividing cells from the cell cycle.  These effects 
were both concentration dependent, and specific to CNTF, as all other neurotrophic 
factors tested had no effect on differentiation.  Furthermore, TH-MYCN tumor cells were 
found to highly express the receptor for CNTF, CNTFR both in vitro and in vivo.  
Testing the ability of CNTF to affect tumor growth in vivo, CNTF treatment attenuated 
subcutaneous tumor growth of the TH-MYCN tumor-derived cell line NHO1S in wild 
type 129/SvJ mice.  Therefore, CNTF signaling may be a potential therapeutic target in 
MYCN-amplified neuroblastoma. 
 In addition to being significantly correlated with a poor prognosis in 
neuroblastoma, the presence of activated TrkB signaling promotes a more aggressive 
phenotype in established neuroblastoma cell lines.  However, whether TrkB signaling is 
sufficient to transform neural crest derived cells had not been established.  To determine 
the role of TrkB signaling in malignant transformation, the two immunoglobulin-like (Ig) 
ligand binding domains were removed from a full length rat TrkB receptor.  Expression 
of this receptor, termed IgTrkB, leads to elevated phosphorylated Erk levels in the 
absence of ligand, indicating the receptor is constitutively active.  When expressed in the 
neural crest derived cell line NCM-1, constitutive TrkB signaling confers a highly 
transformed phenotype characterized by enhanced proliferation, anchorage-independent 
cell growth, anoikis resistance, and matrix invasion.  Furthermore, IgTrkB NCM-1 cells 
upregulate transcripts for a number of cancer promoting genes, in addition to the poor 
prognosis marker MYCN.  In vivo, IgTrkB NCM-1 cells form highly aggressive tumors, 
requiring euthanasia of mice by 15 days following injection, while wild type cells fail to 
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
 
Introduction 
Neuroblastoma is a pediatric cancer arising from the developing tissues of the 
sympathoadrenal lineage of the neural crest.  Although neuroblastoma is the most 
common extracranial solid tumor in children, and the most common cancer in infants, 
little is known about the etiology of the cancer, and disease free survival for stage 3 or 4 
disease with current therapies remains extremely poor.  Neuroblastoma is a uniquely 
heterogeneous cancer in which, in rare cases patients can present with widespread 
metastatic disease that will regress with support treatment alone, while those with high 
risk disease often relapse following intensive chemotherapy.  Thus, prognosis is 
determined less by the size and spread of the tumor, as with most cancers, but more by 
other factors such as, age of diagnosis, tumor histology, as well as the presence or 
absence of genetic and biological variables in the tumor.  To improve patient outcomes in 
the high risk category we can not rely simply on earlier detection, rather, research efforts 
need to focus on alternative strategies, such as identifying factors that can influence 
tumor cell phenotype, and understanding the mechanisms involved in the pathogenesis 
that occurs in the developing sympathetic nervous system that gives rise to high risk 
disease.  These efforts will allow the development of therapeutics that directly target 
these derangements.   
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High risk neuroblastoma tumors often lack differentiation, while more favorable 
tumors are typically more differentiated, more closely resembling the neuronal lineage 
from which they originated.  Therefore, one strategy to treat high risk disease is to 
identify factors which can promote differentiation of these poorly differentiated tumors, 
making them less aggressive, and more amenable to surgical interventions or 
chemotherapeutics.  One of the goals of this dissertation was to identify such factors. 
 
Additionally, although expression of the neurotrophin receptor TrkB and its 
ligand brain-derived neurotrophic factor (BDNF) is correlated with a poor prognosis in 
neuroblastoma, it is not known whether TrkB signaling itself is sufficient to give rise to 
these aggressive tumors.  TrkB regulated tumorigenesis would support this signaling 
pathway as an important drug target in TrkB-expressing neuroblastoma.  Therefore, 
another goal of this dissertation was to determine if TrkB signaling would be sufficient to 




The Disease  
Neuroblastoma represents approximately 8-10% of pediatric cancers but is responsible 
for 15% of all pediatric cancer deaths (Gurney et al., 1997).  Although improvements 
have been made in patient outcomes, long-term survival in those with high risk disease 
remains below 40% (Matthay et al., 1999; De Bernardi et al., 2003).  Neuroblastoma 
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tumors arise from the developing sympathoadrenal lineage.  Although they can be found 
anywhere in the sympathetic nervous system, approximately 50% develop in the adrenal 
medulla, with the rest generally arising in paraspinal ganglia of the abdomen, chest, or 
pelvis (Friedman and Castleberry, 2007).  Presenting symptoms can vary greatly 
depending on primary tumor site and the presence or absence of metastatic disease.  
However, with most tumors arising in the abdomen (65%), symptoms are often vague, 
including fatigue, loss of appetite, and a swollen abdomen.  Clinical presentation for 
neuroblastoma is separated into the three categories of localized, metastatic, and the 
unique case of 4S disease.    
 
Patients have localized disease in 40% of cases of neuroblastoma, with tumors 
ranging from incidental findings on prenatal ultrasonography or chest radiographs, to 
highly invasive local tumors (Maris et al., 2007).  Paraspinal tumors arising along the 
sympathetic chain can present as Horner’s syndrome when found in the cervical region 
(Mahoney et al., 2006), or extend into spinal foramina, causing symptoms of spinal cord 
and nerve root compression (De Bernardi et al., 2005).  Overall, 5-15% of all 
neuroblastoma patients will present with paraspinal tumors, and 5% of all patients will 
present with signs of spinal cord compression, such as motor weakness or sensory loss 
(De Bernardi et al., 2001).  In addition to symptoms of mass effect from tumor growth, 
patients with localized tumors can also present with paraneoplastic syndromes due to 
tumor cell secretion of various factors, or autoimmune responses against tumor cell 
antigens.  These include tumor secretion of vasoactive intestinal peptide (VIP) leading to 
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watery diarrhea and failure to thrive (Kaplan et al., 1980), as well as opsoclonus-
myoclonus syndrome, which can lead to long-term neurological deficits in 70-80% of 
patients (Mitchell et al., 2002).    
 
Unfortunately, as high as 50% of neuroblastoma patients will present with 
widespread metastatic disease, and unlike those with localized disease, are typically very 
ill due to extensive tumor burden.  Metastasies are often found in cortical bone, causing 
bone pain, or the bone marrow, where marrow replacement can occur with symptoms of 
marrow failure such as anemia (Quinn and Altman, 1979).  Additionally, for unknown 
reasons, neuroblastoma can often metastasize to the bony orbit, with patients in these 
cases often presenting with periorbital ecchymoses (bilateral black eyes). 
 
Interestingly, in about 5% of cases, patients will present with metastatic disease 
that will spontaneously regress and be cured by supportive treatment alone.  These 
tumors, termed 4S (special), typically occur in younger patients and consist of small 
primary tumors with metastasis to the liver, bone marrow, and skin (D'Angio et al., 
1971).  Although typically these patients have a favorable prognosis, extensive hepatic 
tumor growth can lead to hepatomegaly and respiratory failure in patients younger than 4 
weeks of age (van Noesel et al., 1997).      
 
Factors Affecting Prognosis 
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Although, as in other neoplasms, the presence of localized versus metastatic disease at 
the time of diagnosis is important in determining prognosis, in neuroblastoma prognosis 
is largely dependent on additional factors including International Neuroblastoma Staging 
System (INSS) stage, age at diagnosis, tumor pathology, MYCN amplification status, as 
well as other genetic and biological variables such as Trk receptor expression.  Because 
of the extreme heterogeneity of disease these many different variables create, 
neuroblastoma prognosis is currently separated into three risk categories: low, 
intermediate, and high (Castleberry et al., 1997).  In general, those with higher risk 
disease have higher stage disease, are diagnosed later in life, and have tumors with 














Table 1-1: Neuroblastoma prognosis risk groups 
*adapted from (Brodeur, 2003) 
INSS 
Stage 
Low Risk Intermediate Risk High Risk 
1 All None None 
2A, 2B Age < 1 yr, or age 1-21 
yrs and MYCN non-
AMP, or age 1-21 yrs 
and MYCN AMP + FH 
None Age 1-21 yrs and 
MYCN AMP + 
UH 
3 None Age < 1 yr and non-
MYCN AMP, or age 1-
21 yrs and MYCN non-
AMP + FH 
Age 0-21 yrs and 
MYCN AMP, or 
age 1-21 yrs and 
MYCN non-AMP 
+ UH 
4 None Age < 1 yr and MYCN 
non-AMP 
Age < 1 yr and 
MYCN AMP, or 
age 1-21 yrs 
4S MYCN non-AMP and 
FH 
MYCN non-AMP and 
UH 
MYCN AMP 
AMP = amplified, UH = unfavorable histology (undifferentiated, higher mitosis-karyorrhexis index, MKI)  
FH = favorable histology (differentiated, lower MKI) 
 
Similar to many other malignancies, surgical staging, as defined by the 
International Neuroblastoma Staging System (INSS) (Brodeur et al., 1993), is an 
important prognostic indicator in neuroblastoma.  Staging ranges from Stage 1 consisting 
of fully resectable localized disease with negative ipsilateral lymph nodes, to stage 4 
patients who present with widespread metastatic disease to the bone marrow or other 
organs.  Although those with the unique 4S subtype of neuroblastoma generally have a 
good prognosis despite metastatic disease, typically, those with higher stage disease have 
less favorable outcomes. 
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In addition to surgical staging, patient age at diagnosis is important in determining 
neuroblastoma prognosis.  Those patients whom are diagnosed at 18 months of age or 
less tend to have much better outcomes, with less aggressive forms of the disease 
(London et al., 2005).  Additionally, age might be an even better predictor of outcomes 
than stage, as infants have much better outcomes than older patients with the same stage 
disease.  These outcomes are not simply dependent on delayed diagnoses, as studies on 
mass-screening at the age of 6 months in Japan detected a 50-100% increase in the 
prevalence of the neuroblastoma, but did not decrease the prevalence of the disease in 
patients over one year of age (Sawada et al., 1984; Woods et al., 1996).  Therefore, if 
anything, mass screening leads to detection of tumors that would have spontaneously 
regressed, subjecting children to unnecessary, and potentially harmful testing, surgery, 
and chemotherapy.  These outcomes suggest the existence of two subtypes of 
neuroblastoma, a biologically favorable form of the disease arising in younger patients 
(the screened population), and biologically unfavorable neuroblastoma forming in older 
patients.   Therefore, the context of sympathetic neural development in which 
neuroblastoma tumorigenesis occurs may be important in determining tumor phenotype.   
 
In addition to stage and age, by evaluating the pathological features of 
neuroblastoma tumors, and relating those features to patient’s clinical outcomes, 
favorable versus unfavorable histology has been developed as another prognostic tool 
(Shimada et al., 1999).  In general, those tumors that are more differentiated, and 
therefore more closely resemble the tissue of the sympathetic nervous system from which 
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they have transformed, possess a more favorable prognosis.  In addition to neuroblast 
differentiation, other histological factors are taken into consideration when deeming a 
tumor favorable versus unfavorable.  These include the amount of Schwann cells present 
in the stroma of the tumor (more being favorable), and the number of mitotic figures and 
degenerating nuclei (mitosis-karyorrhexis index, MKI; lower MKI more favorable).  
Additionally, tumors with a favorable prognosis typically express the neurotrophin 
receptor TrkA, which may promote differentiation in the presence of nerve growth factor 
(NGF), or tumor cell apoptosis in its absence.      
 
Similar to the prognostic significance of age, the genetic features of 
neuroblastoma tumors also suggest the presence of the two differently behaving subsets 
of the disease.  The first type consists of tumor cells with mitotic dysfunction, resulting in 
hyperdiploid or near triploid karotypes with few cytogenic abnormalities such as 
deletions, duplications, or amplifications.  Children with these tumors tend to have more 
favorable outcomes (Kaneko et al., 1987).  On the other hand, poor prognosis tumors 
typically have a near diploid karotype, but gross chromosomal abberations.  Typically 
these aberrations consist of either 11q and 14q deletions, or, in the most aggressive form 
of neuroblastoma, 1p loss of heterozygosity (LOH) and the presence of MYCN 
amplification as either double minutes (DM), or homogeneously staining regions (HSRs) 
(Brodeur et al., 1997).  In fact, the presence of MYCN amplification alone is one of the 
strongest prognostic variables for a poor prognosis in neuroblastoma (Brodeur et al., 
1984).  It is currently unknown what leads to amplification, however it is thought that 
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MYCN might be copied many times to form extrachromasomal circular DNA elements 
(the DMs), which can then be integrated back into a particular locus in a chromosome to 
form the HSRs.  This genetic abnormality is found in approximately 22% of patients 
(Brodeur et al., 1997), and is associated with a rapid tumor progression and a poor 
prognosis even in infants, and in those with lower stages of disease (Seeger et al., 1985).  
Furthermore, TrkB and BDNF are predominantly expressed in MYCN amplified tumors 
(Nakagawara et al., 1994), where they may confer an autocrine survival pathway, while 
TrkA is often expressed in non-MYCN amplified biologically favorable tumors, 
promoting differentiation or apoptosis (Nakagawara and Brodeur, 1997).  Therefore, one 
of the focuses of neuroblastoma research needs to be identifying new strategies and 
treatments for children with MYCN amplified tumors to improve these patient’s 
outcomes.  
 
All of these prognostic variables help categorize patients into the three risk groups 
discussed above, which are based on the probability of death from the disease.  These risk 
groups then dictate the intensity of therapy a patient receives, from surgery alone in low 
risk cases, to dose-intensive chemotherapy, surgery, radiation therapy, bone marrow 
transplant, as well as adjuvant immunotherapy in patients diagnosed with high risk 
neuroblastoma.  Although, risk stratification is fairly clear for those with very low risk, or 
very high risk disease with respect to age and stage, predicting outcomes in patients who 
fall in between has been more difficult.  Recently, a new International Neuroblastoma 
Risk Group (INRG) classification system, separating risk groups into very low, low, 
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intermediate, and high risk, has been proposed to try to better stratify patients to the 
proper treatment strategies (Cohn et al., 2009).  Despite advances in risk stratification, 
these risk groups are simply surrogates for different underlying biological subtypes of 
neuroblastoma.  Therefore, understanding the pathogenesis that gives rise to biologically 
unfavorable neuroblastoma, and developing new therapeutic strategies to treat the 
disease, are crucial to improving outcomes in this patient population.   
 
Genetic Factors Contributing to Disease 
Unlike some cancers, where a single genetic mutation is characteristic of the disease, 
genetic factors leading to neuroblastoma are much more complicated and not well 
known.  Although most cases of neuroblastoma are sporadic, 1-2% of cases do show a 
family history with autosomal dominant inheritance (Shojaei-Brosseau et al., 2004).  
Recently, it was discovered that activating mutations in the anaplastic lymphoma kinase 
(ALK) gene are responsible for the majority of cases of familial neuroblastoma (George et 
al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008), as well as mutated in 5-15% 
of sporadic cases (Chen et al., 2008; George et al., 2008).  The exact function of the wild 
type ALK protein is yet to be fully determined, but it is expressed in the developing 
nervous system (Iwahara et al., 1997; Trochet et al., 2004), and can influence 
proliferation of developing sympathetic precursors (Reiff et al., 2011).  Disruptions of 
another gene, PHOX2B, less common than mutations in ALK, have also been linked to 
familial neuroblastoma.  These missense or frame shift mutations result in loss-of-
function of the Phox2b protein (Mosse et al., 2004; Trochet et al., 2004).  Similar loss-of-
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function mutations have been identified in a small number (2.3%) of sporadic tumors as 
well (van Limpt et al., 2004).   
 
Although mutations of the cell cycle genes CDK6 (Easton et al., 1998) and 
CYCLIND1 (Easton et al., 1998; Molenaar et al., 2003) in single cases have been 
reported, other than ALK and PHOX2B, additional inheritable genetic causes of 
neuroblastoma have been limited to the identification of polymorphisms predisposing to 
an increased risk of disease.  Genome-wide association studies (GWAS) have begun to 
uncover these genetic variations that, along with enumerable other variables, such as 
environmental influences, lead to sporadic neuroblastoma tumorigenesis.  Single 
nucleotide polymorphisms (SNPs) at the putative genes FLJ22536 (Maris et al., 2008) 
and BARD1 (Capasso et al., 2009), and the gene LMO1 (Wang et al., 2011) have been 
identified to be significantly enriched among neuroblastoma patients.  Additionally, in 
the cases of BARD1 and LMO1, these polymorphism code for proteins leading to 
enhanced oncogenic potential (Bosse et al., 2011), confirming their likely role in 
neuroblastoma formation.  
 
Neuroblastoma – a Neural Crest Derived Tumor 
 
Neural Crest Development 
Neuroblastoma is a malignancy arising from the developing sympathoadrenal (SA) 
lineage of neural crest.  The neural crest is a transitory structure that arises from the 
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neural tube early in development following neural tube closure.  Soon after specification 
from the neural tube, trunk neural crest cells undergo an epidermal to mesenchymal 
transition (EMT), becoming a migratory, multipotent population of precursor cells that 
have the ability to differentiate into a number of cell types including glia, melanocytes, 
sensory neurons, and SA precursors (Baroffio et al., 1988; Dupin et al., 1990).  Since 
neuroblastoma can form in the adrenal medulla, in addition to anywhere in the 
sympathetic nervous system, it is thought to arise from this SA precursor population, 
which has the ability to give rise to sympathetic neurons, and the chromaffin cells of the 
adrenal medulla (Anderson et al., 1991).  
 
Specification of neural crest cells to the SA lineage involves the exposure of 
developing neural crest cells to specific growth factors, as well as the expression of 
particular transcription factors (Figure 1-1).  The main family of growth factors 
specifying commitment to the SA lineage is the bone morphogenic protein (BMP) family.  
As shown by inhibition studies, BMPs, which are expressed in the dorsal aorta where 
sympathoadrenal progenitors coalesce following their migration from above the neural 
tube (Shah et al., 1996), are essential for initiation of differentiation to the sympathetic 
lineage (Schneider et al., 1999).  The first pro-neural gene expressed in this progenitor 
population is ASCL1, encoding the basic helix loop helix (bHLH) transcription factor 
hASH1 (or mASH1 and cASH1 in the mouse and chicken, respectively).  Rather than 
induce expression of ASCL1, which is in fact expressed in SA progenitor cells around the 
dorsal aorta prior to BMP expression, BMPs are thought to maintain expression of 
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ASCL1 in SA precursors (Lo et al., 1997).  Following expression ASCL1, further 
specification of SA progenitors involves the coordinated gene expression of ASCL1, 
PHOX2A, PHOX2B, and HAND2 (Hirsch et al., 1998; Stanke et al., 1999; Howard et al., 
2000).   
 
PHOX2B codes for a homeodomain DNA binding protein that plays an important 
role in the development of the SA lineage.  Although hASH1 induces expression of 
PHOX2B, Phox2b can reciprocally induce expression of ASCL1.  Furthermore, Phox2b, 
but not hASH1, is able to induce expression PHOX2A and HAND2.  In turn, Hand2, 
another bHLH transcription factor, then reciprocally upregulates expression of ASCL1 
and PHOX2B, forming an autocrine loop of transcription factor expression promoting 
neural crest progenitor cells to the SA lineage (Bertrand et al., 2002).  Following 
commitment to the SA lineage by this coordinated transcription factor expression, SA 
progenitor cells begin to express neuronal and catecholaminergic specific genes such as 
tyrosine hydroxylase (TH), dopamine beta-hydroxylase (DBH), neurofilament (NF), and 
SCG10, and then migrate from the dorsal aorta to form the secondary sympathetic 
ganglia and adrenal medulla, where further specification to sympathetic neurons and 
chromaffin cells occurs (Huber, 2006).  Further specification of SA progenitors to a 
sympathetic neuronal fate involves expression of a number of proteins including the 
neuroblastoma poor prognosis marker MYCN, another DNA binding transcription factor.   
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Late stage and terminal differentiation to mature sympathetic neurons requires 
subsequent neurotrophin signaling.  Following commitment to sympathetic neurons, SA 
begin to express TrkC and become dependent on the TrkC ligand neurotrophin-3 (NT-3) 
for survival (Birren et al., 1993).  In addition to TrkC, sympathoblasts simultaneously 
transiently express TrkB (Straub et al., 2007).  However, TrkB’s role in sympathetic 
development remains unclear, as there is no apparent sympathetic phenotype in TrkB or 
BDNF-knockout mice (Schober et al., 1997).  Following TrkC expression, 
sympathoblasts begin to express TrkA and their trophic dependence shifts as they 
differentiate to mature sympathetic neurons, with nerve growth factor (NGF) becoming 







Figure 1-1: Sympathetic specification from the neural crest 
*adapted from (Mohlin et al., 2011) 
 
 
Neuroblastoma and the Neural Crest Lineage 
In addition to the simple fact that neuroblastoma can arise anywhere in the distribution of 
the sympathoadrenal lineage, additional lines of evidence from the differentiation of the 
SA from the neural crest confirm neuroblastoma as a malignancy of the developing 
sympathetic nervous system.  ASCL1, the first transcription factor expressed in neural 
crest cells destined for the SA lineage, is expressed at high levels in many 
neuroblastomas (Soderholm et al., 1999; Ichimiya et al., 2001).  This expression suggests 
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that in some cases transformation may occur at this early stage of SA development, or 
alternatively these tumor cells may be reverting back to a less differentiated state.  
Despite this persistence of ASCL1 expression, these cells are able to respond to 
differentiation cues, as differentiation of hASH1 positive neuroblastoma cells by retinoic 
acid treatment leads to down regulation of ASCL1 expression (Soderholm et al., 1999; 
Ichimiya et al., 2001). 
 
Phox2b is also important in both SA development and neuroblastoma.  As 
mentioned above, mutation of the PHOX2B locus is one of the few known causes of 
familial neuroblastoma (Mosse et al., 2004; Trochet et al., 2004; Bourdeaut et al., 2005).  
Interestingly, although mutation in these familial cases leads to loss of function of the 
gene, suggesting PHOX2B to be a tumor suppressor, tumor samples and cell lines 
harboring similar PHOX2B mutations express the downstream target gene DBH, 
suggesting these mutations are not dominant negative (van Limpt et al., 2004; Longo et 
al., 2008).  In any case, disruption of PHOX2B is clearly sufficient to drive 
neuroblastoma formation, although the mechanism involved is yet to be determined.  
Hand2, whose expression is initiated by Phox2b during SA progenitor development, is 
also frequently expressed in neuroblastoma.  However, its expression does not correlate 
with clinical stage (Gestblom et al., 1999), indicating Hand2, unlike Phox2b, is unlikely 
to be a driver of tumorigenesis in neuroblastoma. 
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Expression of MYCN in neuroblastoma, most often in the form of amplification of 
the gene, is well established as a marker of biologically unfavorable tumors.  Like MYC, 
the MYCN protein is known to bind MAX, with this heterodimer activating transcription 
of genes that lead to progression through the G1 phase of the cell cycle, which in the 
brain is important in expansion of the neuronal progenitor cell population (Knoepfler et 
al., 2002).  However, in addition to regulating proliferation, studies in mycn knockout 
mice suggest the transcription factor is important differentiation as well (Sawai et al., 
1993).  Although, at this point it is not clear whether MYCN is predominantly involved 
in proliferation or differentiation during SA development from the neural crest, 
transformation occurring at the MYCN-expressing stage seems to lead to an aggressive 
MYCN amplified form of neuroblastoma.  Furthermore, the importance of MYCN in 
neuroblastoma tumorigenesis is highlighted by the fact that MYCN overexpression alone 
is sufficient to initiate tumor formation, as transgenic mice that express MYCN under the 
tyrosine hydroxylase promoter (TH-MYCN mice) form tumors in 100% of mice 
homozygous for the transgene (Weiss et al., 1997).  Although penetrance of tumor 
formation is highly strain specific, suggesting other factors are likely involved in MYCN-
mediated transformation, TH-MYCN mice provide a model to study primary MYCN 
amplified neuroblastoma tumor cells in culture, as well as in vivo.  Experiments 
described in this dissertation employ the use of this model in an effort to discover growth 
factors that can promote a more differentiated phenotype in MYCN amplified tumor cells. 
 
Trk Signaling  
 18 
 
The Role of Trks in Sympathetic Development 
As mentioned above, neurotrophin signaling through Trk receptors is important in late 
stage sympathetic neuron development; and the role of Trks in neuroblastoma affords a 
more in-depth discussion of neurotrophin signaling in sympathetic development.  
Interestingly, prior to being found to be the high affinity receptor for NGF, the Trk gene 
was first discovered as an oncogene fused to the tropomyosin gene promoting continuous 
proliferation in colon cancer cells.  There are now known to be three members of the 
tropomyosin receptor kinase (Trk) family, TrkA, TrkB, and TrkC to which neurotrophins 
differentially bind (Snider, 1994).  TrkA preferentially binds NGF, TrkB binds BDNF 
and neurotrophin-4/5 (NT-4/5), and TrkC binds neurotrophin-3 (NT-3).  In addition to the 
Trk family of neurotrophin receptors, all members of the neurotrophin family also bind 
the p75, or low affinity nerve growth factor receptor (LNGFR), a member of the tumor 
necrosis factor receptor (TNFR) family (Snider, 1994).  During development, each 
receptor / ligand combination has specific functions.  Signaling through the NGF / TrkA 
ligand-receptor complex supports survival and differentiation of sympathetic neurons and 
sensory neurons that respond to pain and temperature (Smeyne et al., 1994).  BDNF / 
TrkB and NT-4/5 / TrkB signaling supports sensory neurons responsible for relaying 
tactile stimuli and motor neurons respectively, while NT-3 / TrkC signaling supports 
early sympathetic progenitors (Birren et al., 1993) and sensory neurons responsive to 
limb movement and position (Klein et al., 1993; Klein et al., 1994).  
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TrkA expression is abundant throughout the sympathetic nervous system.  As 
mentioned above, TrkA supports survival and differentiation of developing SA 
progenitors into terminally differentiated sympathetic neurons.  During development, 
TrkA expression is detected in most cells by embryonic day (E) 16, and intense labeling 
occurs by E18 in the rat (Ernfors et al., 1992).  In mice, TrkA mRNA expression is 
detected by in situ hybridization starting at E13.5 and increasing through E15.5 until birth 
(Fagan et al., 1996).  Expression is similar in the chick, with TrkA initially seen at E5 
followed by all neurons appearing immunoreactive by E8 (Straub et al., 2007).  
Furthermore, TrkA expression is not restricted to the developmental period, as TrkA is 
highly expressed in the adult sympathetic nervous system of rats (prevertebral, 
paravertebral, and superior cervical ganglia [SCG]), as well as humans (paravertebral 
ganglion) (Wetmore and Olson, 1995; Garcia-Suarez et al., 1996; Schmidt et al., 1998).   
 
Functionally, TrkA signaling is very important in early sympathetic neuron 
survival and development.  This has been established by a number of studies involving 
NGF treatment, and TrkA mutant mice.  Injection of NGF in postnatal mice causes a two- 
to three-fold increase in the size and cell number of SCG and thoracic sympathetic 
ganglia (Levi-Montalcini and Booker, 1960b; Black et al., 1972).  On the other hand, 
treatment with anti-NGF antiserum leads to massive neuronal loss in the postnatal mouse 
SCG (Levi-Montalcini and Booker, 1960a).  These effects are not limited to the postnatal 
period, as transuterine NGF injection leads to an increase in sympathetic neurons, and 
treatment of pregnant mice with antiserum leads to an 80% loss of neurons in the SCG 
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and stellate ganglion of offspring (Kessler and Black, 1980).  In TrkA mutant mice, 
innervation of the submaxillary gland by tyrosine hydroxylase (TH) positive sympathetic 
fibers is disrupted throughout development (Fagan et al., 1996).  Therefore, TrkA 
signaling is critical for the survival of developing sympathetic precursors, and the proper 
development of the sympathetic nervous system. 
 
As mentioned above, like TrkA, TrkC is expressed in the sympathetic nervous 
system, however the majority of this expression is limited to early developmental period 
when TrkC signaling can support early sympathoblast survival.  In the rat, TrkC is first 
expressed at E13, before the onset of TrkA expression at E16 (Ernfors et al., 1992).  After 
E17.5 TrkC expression decreases rapidly to the point that it is reduced by an order of 
magnitude by birth (DiCicco-Bloom et al., 1993).  A similar pattern of expression occurs 
in both the mouse, with the onset of expression at E11.5 increasing to E13.5 and then 
restricted to only a few cells by birth (Fagan et al., 1996), and the chick, with expression 
seen at E6.5 downregulated by E8 (Straub et al., 2007).  In humans, TrkC is expressed in 
only 10% of cells in adult sympathetic ganglia (Garcia-Suarez et al., 1996).  However, 
despite this consistent expression pattern across species, and the ability of TrkC to 
support the survival of early sympathoblasts (Birren et al., 1993), TrkC expression does 
not appear necessary for normal sympathetic development, as TrkC knockout mice show 
no loss of SCG neurons (Tessarollo et al., 1997).  This might be explained by the ability 
of NT-3 to activate TrkA in the absence of TrkC expression.  Indeed, unlike TrkC 
mutants, NT-3 mutant mice have a 35-50% reduction in the number of SCG neurons 
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(Francis et al., 1999).  Thus, although TrkC is consistently expressed in during 
sympathetic development, its expression is not required. 
      
Compared to TrkC, the expression of TrkB in the sympathetic nervous system is 
even more limited.  In the mouse, TrkB expression has been observed in embryonic 
sympathetic ganglia by in situ hybridization (Schecterson and Bothwell, 1992), and 
immunohistochemically at E13 and E15, co-expressed with tyrosine hydroxylase (Straub 
et al., 2007).  Although, in the SCG of 3 day to 4 week old rats, TrkB mRNA is barely 
detectable, it is seen in low but significantly higher levels in the prevertebral ganglia 
(Dixon and McKinnon, 1994).  In the chick, TrkB immunoreactivity has been observed 
transiently in embryonic sympathetic ganglia starting at E5 and was lost by E8 (Straub et 
al., 2007).  Interestingly, these TrkB-expressing sympathoblasts proliferate in response to 
BDNF in culture.  In the adult, unlike TrkA and TrkC, TrkB immunoreactivity has not 
been detected in human sympathetic ganglia, and very few neurons express TrkB mRNA 
in adult rat SCG (Wetmore and Olson, 1995; Garcia-Suarez et al., 1996).  Thus, TrkB 
appears to be expressed in a limited capacity in the developing mammalian and avian 
sympathetic nervous system.   
 
Current evidence suggests TrkB / BDNF signaling has a limited functional role in 
sympathetic nervous system development.  In either BDNF or TrkB mutant mice, there is 
no significant change in SCG size or neuron number (Ernfors et al., 1994; Fagan et al., 
1996).  Although, transgenic mice overexpressing BDNF under the α-mysosin heavy 
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chain promoter show a hyperinnervation of TH-positive neurons in the arrector pili 
muscle in the skin (Botchkarev et al., 1998), whether this effect is mediated through the 
few existing TrkB expressing sympathetic neurons or the low affinity neurotrophin 
receptor p75 has not been established.   
 
The Significance of Trk Receptor Expression in Neuroblastoma   
From the above discussion it is clear that TrkA is highly expressed and instrumental in 
sympathetic nervous system development, TrkC is consistently expressed and appears to 
play an early role, while TrkB expression is limited with no apparent function in normal 
sympathetic development.  These expression patterns and functions in sympathetic 
nervous system development may partly explain the differences in tumor phenotype 
observed in neuroblastoma tumors expressing Trk receptors and their ligands.  
Expression of TrkA or TrkC and their respective ligands are important in sympathetic 
development and differentiation, and there expression in neuroblastoma leads to a less 
aggressive and more differentiated phenotype.  On the other hand, expression of TrkB, 
which has no role in sympathetic differentiation, but can promote proliferation (Straub et 
al., 2007), is correlated with an aggressive and highly proliferative tumor cell phenotype, 
possibly representing cells stuck in a transient sympathoadrenal precursor stage, lacking 
the proper Trk receptor signaling to properly differentiate. 
 
TrkA is expressed in biologically favorable tumors.  High expression of the 
receptor is associated with favorable clinical features, inversely correlated MYCN 
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amplification (Nakagawara et al., 1992), and strongly predictive of a favorable outcome 
(Nakagawara et al., 1993).  TrkA expression is a marker of biologically favorable tumors, 
and likely also contributes to this phenotype, as TrkA expressing tumor cells are able to 
respond to NGF treatment with enhanced survival and terminal differentiation like 
normal sympathetic neurons (Nakagawara and Brodeur, 1997).  Furthermore, consistent 
with the hypothesis of trophic dependence in sympathetic neurons, when these same 
TrkA expressing cells are cultured in the absence of NGF they undergo apoptosis within 
7 days.  The ability of TrkA expressing neuroblastoma to appropriately respond to the 
presence or absence of NGF by differentiating or undergoing apoptosis may explain the 
ability of some favorable neuroblastomas, especially 4S tumors, to spontaneously 
undergo differentiation and regression.  Recently, a developmentally regulated TrkA 
splice variant (TrkAIII) that splices out exons 6, 7, and 9 has been identified (Tacconelli 
et al., 2004).  Interestingly, this splice variant, expressed exclusively in undifferentiated 
neuronal precursors, is constitutively active.  Although, TrkAIII appears to be expressed 
more often in higher stage neuroblastomas, its presence is consistent with the typically 
undifferentiated phenotype of these tumors. 
 
Like TrkA, expression of TrkC is found in biologically favorable neuroblastomas.  
The receptor is expressed in about 25% of primary neuroblastomas, and these tumors 
essentially represent a subset of TrkA-expressing tumors (Yamashiro et al., 1996).  
Furthermore, TrkC-expressing tumors are correlated with younger age, lower stage, and a 
lack of MYCN amplification (Ryden et al., 1996).  NT-3 does not appear to be 
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appreciably expressed in primary neuroblastomas (Yamashiro et al., 1997).  Therefore, 
TrkC, like TrkA in the absence of NGF, may promote apoptosis and regression in the 
more favorable tumors that express the receptor. 
 
Unlike TrkA and TrkC, expression of TrkB and its ligand, BDNF, is a strong 
predictor of an aggressive tumor phenotype and poor prognosis in neuroblastoma.  
Understanding how TrkB, a receptor normally only transiently expressed in the 
developing sympathetic nervous system, contributes to neuroblastoma tumorigenesis is 
crucial to developing successful targeted therapies for poor-prognosis neuroblastoma.  
TrkB and BDNF are predominantly expressed in aggressive, treatment resistant 
neuroblastoma, where this signaling pathway can act in an autocrine manner to promote 
metastasis (Matsumoto et al., 1995; Brodeur et al., 2009).  Tyrosine kinase activated 
signaling pathways are required for TrkB-mediated aggressiveness in neuroblastoma 
tumors, as a truncated TrkB isoform which lacks the tyrosine kinase signaling domain, is 
found in more differentiated tumors such as ganglioneuroblastomas (Nakagawara et al., 
1994).  In these tumors, truncated TrkB can act as a dominant negative inhibitor of full 
length TrkB signaling (Haapasalo et al., 2001)    
 
TrkB signaling promotes an aggressive tumor cell phenotype in neuroblastoma by 
mediating cell growth, survival, adhesion, and metastasis through pathways activated 
normally by Trk signaling; these are the RAS, PI3K, and Rho signaling pathways.  The 
primary signaling pathway involved in promoting cell growth is the Ras-MAPK/Erk 
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signaling cascade.  Upon receptor activation, phosphorylation of the tyrosine residue 
Y490 is followed by phosphorylation of Shc, and recruitment of the adapter protein Grb2 
complexed to the RAS exchange factor SOS.  This complex stimulates RAS by 
promoting activation of the RAS-Raf-MEK-MAPK-Erk pathway, resulting in cell growth 
and proliferation (Kao et al., 2001).  TrkB-mediated cell survival is primarily regulated 
by activation of the PI3K pathway (Yao and Cooper, 1995), which can be both RAS-
dependent, and -independent.  Independent of upstream RAS activation, PI3K can be 
activated through Shc, Grb2, or Irs1 (Reichardt, 2006).  PI3K activation leads to the 
activation of the serine threonine kinase Akt that modulates a number of factors 
important in cell death pathways including Bad, Caspase-9, GSK3, and IB.  TrkB 
activation can also modify adhesion molecules, such as cadherin (Zhou et al., 1997), 
membrane chondroitin sulfate proteoglycan (MCSP) (Schulte et al., 2005), and signaling 
pathways, such as the Cdc42-Rho-Rac-actin pathway (Miyamoto et al., 2006) that are 
important in the regulation of adhesion and metastasis.                 
 
A number of ex vivo studies have further elucidated how TrkB signaling promotes 
a biologically unfavorable phenotype in neuroblastoma.  In the TrkB-expressing 
neuroblastoma cell line, SMS-KCN, treatment with BDNF enhances cell survival in 
serum-free media (Nakagawara et al., 1994; Feng et al., 2001).  Furthermore, BDNF 
treatment of TrkB-expressing neuroblastoma cells enhances their invasiveness 
(Matsumoto et al., 1995; Cimmino et al., 2009), and renders them less sensitive to 
cytotoxic drugs (Scala et al., 1996; Ho et al., 2002; Jaboin et al., 2002; Li et al., 2005; Li 
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et al., 2007; Baj and Tongiorgi, 2009).  In addition, TrkB activation by BDNF in SY5Y 
neuroblastoma cells increases production of the pro-angiogenic molecule VEGF 
(Nakamura et al., 2006), while expression of TrkA down-regulates expression and 
function of angiogenic stimulator in this same cell line (Eggert et al., 2002).  Therefore, 
concomitant expression of both full length TrkB and BDNF likely forms an autocrine or 
paracrine survival pathway in the associated aggressive poor prognosis tumors. 
 
Furthermore, an active TrkB signaling pathway may be important in the 
propensity of a high risk patient population to succumb to relapse following 
chemotherapy.  It has been shown that neuroblastoma cells that survive repeated 
exposures to cytotoxic drugs express increasing levels of BDNF; this may help confer 
survival and multidrug resistance in these cells (Matsumoto et al., 1995).  The increases 
in BDNF levels, coupled with hypoxia, cause increases in TrkB expression (Martens et 
al., 2007), and may provide a situation in which the microenvironment within the tumor 
is able to respond to environmental insults (such as chemotherapeutics) to promote 
survival of tumor cells, and eventual relapse.  These survival effects are mediated in part 
by activation of PI-3kinase (Jaboin et al., 2002) and Akt (Li et al., 2005), and inactivation 
of GSK3 (Li et al., 2007), as in normal Trk expressing cells.  Additionally, even in 
tumor cells in which TrkB expression is low, local environments rich in BDNF may be 
able to support the survival of these cells and protect them from chemotherapeutics, 
setting the stage for later relapse.  For instance, in multiple myeloma, bone marrow-
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derived BDNF is able to activate TrkB-expressing multiple myeloma cells and promote 
drug resistance via the PI-3kinase / Akt pathway (Pearse et al., 2005).   
 
As well as increasing survival in neuroblastoma cells, activation of the TrkB 
signaling pathway also promotes migration, invasiveness, and metastatic potential.  In 
SY5Y and SK-N-AS neuroblastoma cells, TrkB signaling enhances tumor cell 
invasiveness in an autocrine manner, increasing the expression of hepatocyte growth 
factor (HGF) and its receptor, c-MET (Hecht et al., 2005).  Furthermore, in vitro, SY5Y 
cells transfected with TrkB, but not those transfected with TrkA, display increased 
invasiveness mediated by upregulation of galectin-1 (Gal-1) (Cimmino et al., 2009).  
Thus, research with neuroblastoma cell lines demonstrates the ability of TrkB signaling 
to promote a more aggressive tumor cell phenotype, suggesting the expression of TrkB / 
BDNF is causal in the aggressive and biologically unfavorable nature of tumors that 
express the receptor and ligand.  
 
Despite evidence demonstrating the role of TrkB signaling in neuroblastoma cell 
lines, there has been little in vivo work showing how aberrant TrkB signaling might 
contribute to tumorigenesis, or whether TrkB signaling is sufficient to transform normal 
neural crest precurors.  Developing sympathoadrenal precursors transiently express TrkB 
in vivo, and are able to proliferate in response to BDNF ex vivo (Straub et al., 2007), 
suggesting that aberrant TrkB signaling in vivo may be sufficient to cause transformation 
in neuroblastoma.  By examining the effects of expression of a constitutively active TrkB 
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receptor in a neural crest derived cell line, experiments presented in this dissertation 
suggest TrkB signaling can be an initiator of tumor formation in neuroblastoma.  
 
Summary 
Taking into account the development of the sympathoadrenal lineage from the neural 
crest, the heterogeneity of disease seen in neuroblastoma tumor phenotypes is likely a 
result of tumors arising from different points in the developmental program.  It seems 
likely that biologically unfavorable tumors arise from an earlier point in development, 
and like early precursors, are undifferentiated, highly proliferative, and express TrkB.  On 
the other hand, biologically favorable tumors appear to arise later in development, and 
more closely resemble normal sympathetic neurons by virtue of expressing TrkA and 
TrkC, and responding appropriately to differentiation / apoptotic cues transmitted by 
these receptors.  Ultimately, the development of new strategies that can shift poor 
prognosis tumors to the more differentiated state of biologically favorable tumors may be 
of therapeutic benefit.  Furthermore, determining what aspects of biologically 
unfavorable tumors – such as MYCN amplification or TrkB signaling – are sufficient to 
drive neuroblastoma formation, will be important in targeting specific therapeutics for 
these derangements.    
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Neuroblastoma is a pediatric malignancy arising in tissues of the sympathoadrenal 
lineage.  Elevated expression of the transcription factor MYCN in tumor tissue is 
associated with poor clinical outcomes, and MYCN overexpression targeted to the neural 
crest lineage by the tyrosine hydroxylase (TH) promoter is sufficient to cause 
neuroblastoma in transgenic mice (TH-MYCN).  Ciliary neurotrophic factor (CNTF) is a 
neuropoietic cytokine known to influence survival, differentiation, and proliferation in 
developing sympathetic neurons; therefore we determined whether TH-MYCN tumors 
respond to CNTF by differentiating.  We found that TH-MYCN tumors predominantly 
arise in the celiac ganglia and many cells express CNTFR alpha.  In cell culture, CNTF 
increases process outgrowth and decreases proliferation of cells derived from TH-MYCN 
tumors with an EC50 of approximately 0.4 ng/mL. CNTF promotes differentiation by 
first inducing cell cycle withdrawal rather than by causing a non-mitotic population to 
extend neurites.  In vivo, CNTF treatment attenuated subcutaneous tumor growth of the 
TH-MYCN tumor-derived cell line NHO1S in wild type 129/SvJ mice.  Thus, activation 
of the CNTF receptor overrides the proliferative effect of N-MYC, suggesting a possible 
therapeutic target for poor prognosis, MYCN amplified tumors. 
 
Introduction 
Neuroblastoma is the most common extracranial solid tumor in children, and outcomes 
remain poor for many patients who present with the cancer at 18 months or older.  
Prognosis is stratified into low, intermediate, and high risk categories (Maris et al., 2007) 
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based on the biological heterogeneity of the disease, with the most consistent genetic 
aberration correlating with high risk disease being amplification of the MYCN gene, 
which occurs in approximately one third of primary tumors (Maris and Matthay, 1999).  
These poor prognosis MYCN amplified tumors are typically stroma-poor and lack 
differentiation, while non-amplified tumors, tend to be stroma-rich, less aggressive, and 
more differentiated, suggesting factors in the tumor microenvironment may be important 
in determining tumor phenotype (Shimada et al., 1984).  Furthermore, MYCN expression 
can disrupt responses to normal developmental cues, as sympathetic neurons 
overexpressing the MYCN protein reenter S phase and resist cell death induced by nerve 
growth factor (NGF) withdrawal (Wartiovaara et al., 2002).  Therefore, agents promoting 
differentiation of MYCN amplified tumors may improve outcomes in high risk 
neuroblastoma.   
 
 Previously, a mouse model of neuroblastoma was generated by targeting 
expression of MYCN to the neural crest lineage using the rat tyrosine hydroxylase (TH) 
promoter (Weiss et al., 1997).  100% of mice homozygous for the TH-MYCN transgene 
develop tumors, however tumor penetrance is strain specific, as mice on the C57B6/J 
background develop tumors by 16 weeks of age (Hansford et al., 2004), as opposed to 
only 6.5 weeks in 129/SvJ mice carrying the transgene.  These tumors show typical 
histopathological features of human neuroblastoma (Moore et al., 2008), as well as 
genetic aberrations similar to those found in the human disease (Weiss et al., 2000; 
Hackett et al., 2003).  Therefore, TH-MYCN mice represent a mouse model for studying 
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MYCN expressing primary tumor development, as well as the properties of MYCN 
expressing primary tumor cells in culture.   
 
 In addition to the presence or absence of MYCN amplification, the degree of 
tumor differentiation, which in both normal neuronal development and neuroblastoma is 
influenced by growth factor signaling, is another important factor in determining patient 
prognosis.  Children diagnosed with tumors with increased differentiation have a better 
probability for disease-free survival (Shimada et al., 1984).  Differentiation is influenced 
predominantly by the NGF/TrkA and BDNF/TrkB growth factor signaling pathways, 
with TrkA expressed primarily in more differentiated biologically favorable tumors and 
an active TrkB pathway often found in poor prognosis MYCN-amplified cases 
(Nakagawara et al., 1993; Nakagawara et al., 1994).  Furthermore, transfection of SY5Y 
neuroblastoma cells with the TrkA receptor confers on these cells the ability to 
differentiate in response to NGF (Lavenius et al., 1995), while conversely, transfection 
with the TrkB receptor renders these cells resistant to chemotherapeutics (Ho et al., 
2002).  In addition to TrkA and TrkB, other growth factor pathways have been shown to 
be important in determining neuroblastoma tumor cell phenotype.  Activation of the 
epidermal growth factor receptor (EGFR) promotes proliferation in SY5Y and NLM cells 
(Ho et al., 2005), and SMS-KCNR cells differentiated by retinoic acid express 
transforming growth factor beta 1 (TGF-beta 1) and its receptors (Cohen et al., 1995).   
Little is known about the effects of other factors known to be trophic in sympathetic 
neurons.    
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 Here we report that the neuropoietic cytokine, ciliary neurotrophic factor (CNTF), 
promotes differentiation and cell cycle withdrawal in tumor cells isolated from TH-
MYCN mice.  Furthermore, CNTF treatment attenuates growth of the TH-MYCN tumor-
derived cell line NHO1S in vivo.  These results suggest the CNTF signaling pathway may 
represent an important target for differentiating poor prognosis MYCN-expressing tumors.  
 
Materials and methods 
Ethics Statement: This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health.  The protocol was approved by the Institutional Animal 
Care and Use Committee of the University of Vermont (Animal Welfare Assurance 
Number, A3301-01; IACUC protocol number 07-114). Every effort was made to 
minimize suffering of the animals used. 
 
Mice: TH-MYCN mice homozygous for the human MYCN cDNA under the rat tyrosine 
hydroxylase promoter (Weiss et al., 1997) on a 129/SvJ genetic background were used 
for all experiments involving TH-MYCN tumor removal and growth in culture.  WT 
129/SvJ mice were used for in vivo experiments with NHO1S cells, a cell line derived 
from TH-MYCN mouse tumors.   
 
 51 
Immunostaining: Tumors were removed and immersion fixed overnight in Zamboni's 
fixative (4% (w/v) paraformaldehyde, 15% (v/v) picric acid in 0.1 M sodium phosphate 
buffer, pH 7.4).  Tumors were washed with PBS to remove fix and equilibrated in 15%, 
and then 30% sucrose overnight at 4C. Tissue sections of 20 mm thickness were cut 
using a Microm HM 560 cryostat (Thermo Scientific) and mounted on SuperFrost Plus 
slides (Fisher Scientific).  Sections were post-fixed 15 minutes in Zamboni’s fixative and 
placed into blocking solution (1x PBS consisting of 10% (v/v) heat-inactivated horse 
serum (Invitrogen), 0.5% Triton X-100 (Sigma), and 0.1% sodium azide (Fisher 
Scientific)) overnight at 4C.  Sections were stained with primary antibodies overnight at 
4C, followed by secondary antibodies for three hours at room temperature (see below for 
specific antibodies).  Slides were then incubated in PBS + Hoechst (1:2000, Invitrogen) 
for five minutes at room temperature to stain nuclei and mounted with Mowiol (EMD 
Millipore). After staining, coverslips were mounted on slides with Permafluor (Thermo 
Scientific) containing Hoechst (1:2000, Invitrogen).  Images were captured using a Nikon 
C1 confocal mounted on a Nikon Eclipse E800 microscope with a 60× Plan Apo (NA 
1.4) oil objective lens, E7-C1 software, and UV, Argon, and He/Ne lasers exciting at 408, 
488, and 543 nm and emitting at 404 500–530, and 555–615 nm, respectively. 
 
Antibodies: Primary antibodies used were as follows.  Chicken anti-tyrosine hydroxylase 
(1:250, Aves), rabbit anti-ki67 (1:200, Novacastra), rabbit anti-CNTFRa (1:30, a 
generous gift from Dr. Hermann Rohrer of the Max Planck Institute for Brain Research, 
Frankfurt, Germany), mouse anti-3A10 (neurofilament associated antigen, 1:1, 
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Development Studies Hybridoma Bank), sheep anti-BrdU (1:100, Biodesign).  Secondary 
antibodies were donkey anti-rabbit alexa 488 (1:1666, Invitrogen), donkey anti-mouse 
cy3 (1:1000, Jackson), donkey anti-rabbit cy3 (1:1000, Jackson), and donkey anti-goat 
alexa 488 (1:1000, Invitrogen).    
 
Cell culture: All cells were grown at 37C in 5% CO2.  To obtain TH-MYCN tumor cells, 
tumors were removed from homozygous TH-MYCN mice at 35 days of age and 





-free balanced salt solution) to produce a single cell suspension.  Cells were 
then plated on poly-D-lysine (0.5 mg/mL, Sigma) and laminin (0.02 mg/mL, purified in 
the Nishi lab from EHS tumors grown subcutaneously in C57Bl6 mice) coated coverslips 
(Fisher Scientific) at 50,000 cells per well in a 24-well tissue culture plates (Falcon).  
Cells were grown in 20 U/mL penicillin, 20 mg/mL streptomycin, 2mM L-glutamine, and 
6 mg/mL glucose in modified L15CO2 supplemented with B27 (1:50, Invitrogen).  
Growth factors were added upon plating and consisted of the following – CNTF (5, 1, 
0.5, and 0.25 ng/mL, Alomone), BDNF (10 ng/mL, R&D), LIF (10 ng/mL, R&D), 7s 
NGF (1 g/mL, Alomone), NT-3 (30 ng/mL, R&D), and GDNF (10 ng/mL, Peprotech).  
NHO1S cells (a generous gift from Dr. Michelle Haber of the Children’s Cancer Institute 
Australia (Cheng et al., 2007)) were maintained in 10% fetal calf serum, 20 U/mL 
penicillin, 20 mg/mL streptomycin, 2mM L-glutamine, and 6 mg/mL glucose in modified 
L15CO2.  For CNTF experiments, NHO1S cells were plated on poly-D-lysine and 
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laminin coated coverslips at 10,000 cells per well in a 24-well plates.  Cells were treated 
in culture with CNTF (5 ng/mL).    
 
Quantification of process outgrowth and proliferation: Following staining, process 
outgrowth and proliferation were quantified with the use of a Nikon Eclipse E800 
microscope connected to a computer equipped with StereoInvestigator software (MBF 
Bioscience, Williston, VT) in the COBRE Molecular/Cellular Core Facility.  The 
percentage of ki67 stained cells was quantified using the fractionator program of 
StereoInvestigator.  Briefly, after creating a defined counting area, the program selected 
random views within the area to quantify staining and obtain an estimate of the total 
population.  Process outgrowth was measured using Neurolucida (MBF Bioscience, 
Williston, VT).  For each coverslip, 16 random views were selected in which to measure 
process length.  In order to derive the process length per cell value for each condition, the 
total process length from the 16 random views was divided by the cell population (as 
determined with StereoInvestigator). 
 
RNA extraction and qPCR: For RNA extraction from NHO1S cells, cells were grown to 
confluence in 6-well plates, lysed directly into TRI Reagent (Molecular Research 
Center), and RNA was isolated using the manufacturer’s protocol.  RNA (1g) was 
transcribed to cDNA using superscript III (Invitrogen) and random hexamer priming 
(Invitrogen).  cDNA was then diluted 1:5 and CNTFRa and 18S RNA expression were 
quantified by qPCR with the use of FAM/BHQ labeled primer/Taqman probe mixes 
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(ABI) and an ABI 7700 machine in the Molecular Cellular Core operated by the Center 
of Biomedical Research Excellence (COBRE) in the Neuroscience department at the 
University of Vermont.  RNA samples from at least three separate cell cultures were 
quantified.  
 
In vivo CNTF treatment and NHO1S tumor growth: NHO1S cells, generously provided 
by Dr. Michelle Haber, Children's Cancer Institute Australia for Medical Research, 
Randwick, Australia, were grown to confluence in T75 culture dishes.  Cells were 
injected subcutaneously into the flank of WT 129/SvJ mice (N=12) at 1 million cells per 
mouse in 200 L of Matrigel (BD Biosciences).  When tumors became palpable, in vivo 
treatment with CNTF was begun.  Mice received an intraperitoneal injection of either 
saline or CNTF (0.2 mg/kg, in saline), daily for 7 days (6 mice per condition).  Tumor 
growth was quantified by length and width caliper measurement daily by an observer 
blinded to the treatment condition.  Tumor volume was estimated from length and width 
measurements using the formula v = 1.58(/6)(L*W)^(3/2) (Feldman et al., 2009).  The 
day following the final CNTF or saline injection, final tumor dimensions were measured 
and mice were euthanized. 
 
Results 
Tumor development in homozygous TH-MYCN mice 
Similar to previous observations of tumor formation in TH-MYCN mice on the 129/SvJ 
background, 100% of homozygous mice examined formed palpable tumors by an average 
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of 49.5 + 0.84 days of age (Table 1).  Tumors were large, highly angiogenic, and formed 
predominantly in the area of the celiac prevertebral ganglion, as in hemizygous mice 
(Chesler et al., 2007).  In 2 of 14 mice observed for tumor formation, asymmetrical 
enlargement of the superior cervical ganglion was found in addition to abdominal tumor 
formation.  In one mouse, along with prevertebral tumor formation, a separate tumor 
developing along the sympathetic chain was also observed.      
 
CNTF promotes differentiation of TH-MYCN tumor cells in vitro 
In order to investigate whether growth factor treatment could influence the phenotype 
of tumor cells from TH-MYCN mice, tumors were isolated from 35 day old 
homozygous mice, and dissociated tumor cells were treated with brain-derived 
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell-derived 
neurotrophic factor (GDNF), leukemia inhibitory factor (LIF), nerve growth factor 
(NGF), neurotrophin 3 (NT-3), or a combination of NGF and NT-3.  After 4 days in 
culture, treatment with CNTF and LIF, but not other growth factors promoted 
approximately a 4-fold increase in process outgrowth (Fig. 2-1A, grey bars, p < 0.01), 
as well as a 15% reduction in proliferation, as measured by ki67 staining (Fig. 2-1A, 
black bars, p < 0.05).  After 3 days in culture, CNTF-treated tumor cells were visibly 
more differentiated than untreated cells (Fig. 2-1B and C).  Whereas both CNTF and 
LIF signaling involves the LIFRb and GP130 receptor signaling subunits, CNTF 
signaling requires the additional presence of a CNTFRa subunit, a glycosyl-
phosphoinositide-linked co-receptor commonly expressed in cells of both the 
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peripheral and central nervous system (Heller et al., 1996), which binds ciliary 
neurotrophic factor (CNTF) (Ip et al., 1993).  Therefore, the differentiating effects of 
CNTF rather than LIF on TH-MYCN tumor cells were investigated further.  
 
When quantifying CNTF-induced process outgrowth and inhibition of 
proliferation after 1, 2, and 3 days of CNTF treatment, we found that CNTF-induced 
effects reached significance after 3 days of treatment (Fig. 2-2A and B, p < 0.0001).  No 
significant changes in cell number were observed over the same time course of CNTF 
treatment (Fig. 2-2C), indicating that the effect of CNTF on differentiation and 
proliferation was not the result of a selective survival advantage.  The effects of CNTF 
were concentration-dependent, (p < 0.01), with an EC50 of approximately 0.4 ng/mL for 
the effects on neurite outgrowth (Fig. 2-2D) and proliferation (Fig. 2-2E), similar to the 
EC50 observed in CNTF-induced decreases in proliferation of embryonic chick 
sympathetic neurons (Ernsberger et al., 1989).  In addition, we did not observe a 
concentration-dependent effect of CNTF on cell number (Fig. 2-2F).   
 
The decrease in cell proliferation observed in the presence of CNTF could result 
from either a selective survival advantage provided to non-proliferating cells by CNTF, 
or as a result of CNTF promoting actively dividing cells to withdraw from the cell cycle.  
In order to distinguish between these two possibilities, we identified dividing cells before 
and after CNTF treatment (Fig. 2-3A).  Upon plating, bromodeoxyuridine (BrdU) was 
added to the culture medium, and cells were treated with or without CNTF.  After 24 
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hours, the BrdU was washed out, and the media and CNTF were replaced.  BrdU 
incorporated into the DNA of tumor cells undergoing S-phase during this first 24-hour 
period.  After an additional 48 hours in culture, tumor cells were fixed and stained for 
BrdU (Fig. 2-3B and D), and Ki67, which stains cells dividing at the time of fixation 
(Fig. 2-3C and E).  Indicating CNTF promotes actively dividing cells to withdraw from 
the cell cycle, CNTF treatment caused a ~30% decrease in the percentage of BrdU 
positive cells that stained positive for Ki67 (Fig. 2-3E, p < 0.0001).  
 
CNTFR is expressed in tumor cells in vitro and in vivo 
In order to distinguish the extent of CNTFR expression in the population of tumor cells 
we were treating, we examined CNTFR expression in cultured tumor cells treated with 
or without CNTF.  CNTFR was highly expressed in cells stained immediately after 
plating (Fig. 2-4A and B), and in cells treated with or without CNTF for 3 days (Fig. 2-
4B), with an increase in expression after 3 days in culture.  Suggesting the majority of 
tumor cells have the ability to differentiate in response to CNTF, CNTFR was 
expressed in greater than 70% of cultured tumor cells in all conditions (Fig. 2-4A and B).  
Furthermore, despite arising from tissue of the sympathetic nervous system, the majority 
of cultured tumor cells lacked staining for tyrosine hydroxylase (TH), the rate-limiting 
enzyme in catecholamine synthesis (Fig. 2-4A). 
 
We determined that CNTFR was highly expressed in cultured TH-MYCN tumor 
cells.  To determine if the receptor is expressed in TH-MYCN tumors in vivo, and 
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therefore may respond to in vivo CNTF treatment, we examined expression of the 
receptor, as well as other markers, in tumors from TH-MYCN mice.  As in cell culture 
experiments, tumors were isolated from homozygous mice at 35 days of age.  Consistent 
with our ex vivo results, CNTFR was also expressed in the majority of tumor cells in 
vivo (Fig. 2-4C).  Furthermore, qPCR of mRNA isolated from homozygous TH-MYCN 
tumors revealed a level of CNTFR expression equivalent to that of the superior cervical 
ganglion (Fig. 2-4D).  Also consistent with in vitro TH-MYCN tumor cells, as well as a 
previous study following tumor development in hemizygous TH-MYCN mice (Chesler et 
al., 2007), the majority of TH-MYCN tumors stained strongly for Ki67 in vivo, indicating 
a high rate of proliferation in homozygous TH-MYCN tumors (Fig. 2-4E and F).  
Furthermore, as we observed in vitro, TH expression was limited in vivo, and found only 
in small Ki67-negative clusters throughout the tumor (Fig. 2-4E and F).    
 
Efficacy of CNTF on tumor growth in vivo 
After investigating the differentiating effects of CNTF in vitro, we next determined if 
CNTF could inhibit TH-MYCN tumor cell growth in vivo.  To measure tumor growth 
over the course of CNTF treatment, we used a syngenic in vivo tumor growth model 
using subcutaneous injection of a cell line derived from TH-MYCN tumors into wild type 
129/SvJ mice.  In this model, tumor growth can be easily controlled and observed, as it 
eliminates waiting for tumor development in homozygous mice, and tumors can be easily 
monitored as they grow subcutaneously rather than in the abdominal cavity.  Previously, 
cell lines had been derived from TH-MYCN tumors by Cheng et. al. (Cheng et al., 2007).  
 59 
Screening a few of these cell lines for responsiveness to CNTF, we identified the line 
NHO1S to be most representative of primary TH-MYCN tumor cells; it abundantly 
expresses the CNTFR receptor and the proliferation marker ki67, expresses low levels 
of TH (Fig. 2-5A and B), and differentiates in response to in vitro CNTF treatment (Fig. 
2-5C-E).  Therefore, NHO1S cells are an appropriate cell line to model in vivo CNTF 
treatment of TH-MYCN tumor cells.      
 
To assess the ability of CNTF to inhibit in vivo tumor growth, 1 million NHO1S 
cells suspended in 200 L of Matrigel were injected subcutaneously into 12 wild type 
129/SvJ mice.  When tumors first became palpable, mice began to receive a daily 
intraperitoneal injection for 7 days of either saline, or CNTF at 0.2 mg/kg in saline.  
Tumor size was monitored daily by an observer blinded to treatment.  CNTF treatment 
attenuated tumor growth over the course of the experiment.  This was marked by a 
significant reduction (Fig. 2-5F, p < 0.01) in the fold tumor size (tumor size divided by 
starting tumor size) in mice injected with CNTF compared to saline injected mice 7 days 
following the first injection.  Therefore, in addition to the ability to promote 
differentiation in vitro, CNTF is able to attenuate TH-MYCN tumor growth in vivo.  
Furthermore, as CNTF is known to cause weight loss in mice (Henderson et al., 1994; 
Lambert et al., 2001), mouse weight was measured daily to ensure that CNTF treatment 
did not result in an unhealthy reduction in weight.  Mice receiving CNTF were observed 
to lose a modest 15% of their starting body weight over the course of the experiment 




The principal finding of this study is that CNTF reduces TH-MYCN tumor cell growth by 
reducing cell proliferation and promoting cell differentiation.  Of the neurotrophic factors 
tested, only the neuropoietic cytokines CNTF and LIF produced this effect.  Furthermore, 
systemic treatment of animals with CNTF attenuated subcutaneous TH-MYCN-derived 
tumor cell growth.  Taken together, our data suggest that a further understanding of the 
molecular mechanisms involved in neuropoietic cytokine signaling could be beneficial in 
developing adjuvant differentiating therapies in neuroblastoma.    
 
Since the discovery of CNTF as a growth factor with the ability to support the 
survival of chick embryonic ciliary ganglion neurons (Varon et al., 1979; Lin et al., 1989; 
Stockli et al., 1989; Eckenstein et al., 1990), it has been appreciated that CNTF can have 
a variety of effects on cells of the nervous system.  CNTF treatment promotes survival of 
cultured embryonic motor neurons (Arakawa et al., 1990; Oppenheim et al., 1991), 
sympathetic (Eckenstein et al., 1990), and sensory neurons (Eckenstein et al., 1990; 
Thaler et al., 1994). Treatment of neuroblasts isolated from the sympathetic ganglia of E7 
chicken embryos with CNTF promotes the early expression of vasoactive intestinal 
peptide (VIP), which is not normally expressed until E10 (Ernsberger et al., 1989).  
Furthermore, CNTF induces choline acetyltransferase (ChAT) immunoreactivity in E12 
cultured sympathetic neurons, but not at E7 (Ernsberger et al., 1997).  In the rat, CNTF 
has similar effects, inducing ChAT expression of neonatal superior cervical ganglion 
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neurons.  In addition, it simultaneously diminishes the expression of tyrosine hydroxylase 
(TH) (Saadat et al., 1989).  In the central nervous system (CNS), CNTF can support the 
survival of cultured hippocampal neurons (Ip et al., 1991), prevents the degeneration of 
medial septal neurons (Hagg et al., 1992), and promotes neurogenesis in the forebrain by 
increasing neural stem cell proliferation (Emsley and Hagg, 2003).   
 
Similar to the effect on cultured E7 chicken sympathetic neuroblasts, we see that 
CNTF inhibits proliferation of primary cultured TH-MYCN neuroblastoma cells.  
Although CNTF is able to lead to a ~30% reduction in the number of proliferating cells in 
both embryonic sympathetic neurons and TH-MYCN tumor cells (see figure 2-3), many 
TH-MYCN tumor cells remain dividing following CNTF treatment (40%) compared to 
CNTF treatment in embryonic sympathetic neurons (7%) (Ernsberger et al., 1989).  In the 
sympathoadrenal progenitor cell line (MAH), which is able to differentiate into 
chromaffin-like and sympathetic neuron-like cells, CNTF promotes terminal 
differentiation into a neurofilament positive sympathetic phenotype in vivo (Doering et 
al., 1995), similar to what we have observed here.  Interestingly, in neuroblastoma, 
patients whose tumors express high mRNA levels of either CNTF or CNTFR have 
improved survival over patients whose tumors have low expression of the two transcripts 
(http://home.ccr.cancer.gov/oncology/oncogenomics/). 
 
While tumor cells from the TH-MYCN mouse model of neuroblastoma respond 
to CNTF treatment by differentiating, responses of CNTFR-expressing human 
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neuroblastoma cells to CNTF remain hard to predict.  Consistent with what we observed, 
the MYCN-amplified neuroblastoma cell lines LA-N-2 and SK-N-BE, respond to CNTF 
treatment with enhanced neurite outgrowth marked by an increased number of tumor 
cells with neurites, and increased neurite length (Rossino et al., 1995).  However, in the 
neuroblastoma cell line SY5Y, from which the CNTFR receptor was originally cloned 
(Squinto et al., 1990), treatment with CNTF activates the JAK-STAT pathway 
downstream of CNTFR, but does not cause tumor cell differentiation (Rossino et al., 
1995; Halvorsen et al., 1996).  Furthermore, although CNTF treatment induces 
expression of the neurotrophin receptor TrkA in both GOTO and HTLA230 
neuroblastoma cell lines, subsequent treatment with the TrkA ligand NGF results in 
proliferation in GOTO cells, but differentiation in HTLA230 cells (Bogenmann et al., 
1998). 
 
We used the TH-MYCN tumor-derived cell line NHO1S to determine whether 
CNTF can attenuate TH-MYCN tumor cell growth in vivo.  For several reasons, we 
believe this cell line to be representative of the primary TH-MYCN tumor cells used in 
our in vitro experiments.  This cell line is one of 6 cell lines that have been derived from 
TH-MYCN tumors (Cheng et al., 2007), and is one of four of these 6 cell lines that have 
been derived from homozygous TH-MYCN mice, similar to the primary cells used here.  
Furthermore, this cell line, and not other cell lines tested, like primary TH-MYCN tumor 
cells, abundantly expresses CNTFR, and differentiates in response to CNTF treatment.  
Finally, similar to primary TH-MYCN tumor cells, the majority of NHO1S cells divide in 
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culture as indicated by abundant Ki67 staining, while expression of the sympathetic 
marker tyrosine hydroxylase is limited to rare cells.  Therefore, we feel that NHO1S cells 
are an appropriate cell line to model the effect of CNTF on TH-MYCN tumor growth in 
vivo. 
 
Despite the encouraging prospect of CNTF as a novel differentiating agent to 
limit growth of neuroblastoma tumors, the idea of CNTF as a therapeutic must be 
approached with caution.  Previously, a recombinant human CNTF (rhCNTF) was tested 
in the treatment of amyotropic lateral sclerosis (ALS) following the discovery of the 
ability of CNTF to support the survival of motor neurons in vitro (Sendtner et al., 1990) 
and in vivo (Mitsumoto et al., 1994).  Unfortunately, in addition to proving ineffective at 
treating ALS (Bongioanni et al., 2004), CNTF treatment had the adverse side effect of 
inducing anorexia and doubling the death rate in those treated at higher doses (Miller et 
al., 1996).  Consistent with the observed ability of CNTF to cause weight loss in both 
human (Ettinger et al., 2003) and animal (Lambert et al., 2001) studies, in the current 
study, CNTF-treated mice consistently lost 15% of their body weight over the course of 
the experiment, suggesting that CNTF may not be a realistic therapy for neuroblastoma.  
Interestingly however, recently a rhCNTF fusion protein was developed (TAT-CNTF), 
which is able to rescue rat motor neurons from cell death following sciatic nerve 
transection without the typical 20-30% decrease in body weight seen in rhCNTF treated 
animals (Rezende et al., 2009).  Although the work presented here implicates CNTF as a 
novel differentiating agent in neuroblastoma, elucidating the mechanisms involved in 
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CNTF-induced differentiation might be of greater therapeutic benefit in the future 
treatment of poor prognosis tumors. 
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1033-3 F 50 Abdominal tumor 
1039-1 F 50 Abdominal tumor 
1042-1 M 54 Abdominal tumor 
1042-2 M 52 Abdominal tumor 
1042-3 M 49 Abdominal tumor 
1048-2 M 48 Abdominal tumor 
1048-7 M 44 Abdominal tumor 
1051-2 M 51 Abdominal tumor 
1051-5 M 51 Abdominal tumor 
1051-7 M 52 Abdominal tumor, left SCG 4x larger than right 
1052-1 M 51 Abdominal tumor 
1052-4 M 50 Abdominal tumor, right SCG 2x larger than left 
1054-1 F 49 Abdominal as well as sympathetic chain tumor 
1054-2 M 42 Abdominal tumor 




Figure 2-1: Growth factor effects on process outgrowth and proliferation of TH-
MYCN tumor cells in culture   
(A) Ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF), which both 
activate the CNTF receptor, significantly increase process outgrowth (grey bars, p < 0.01, 
ANOVA, n=5) and inhibit proliferation (black bars, p < 0.05, ANOVA, n=5) in tumor 
cells derived from TH-MYCN mice after 4 days in vitro compared to control, brain-
derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), 
nerve growth factor (NGF), neurotrophin-3 (NT3), and NGF and NT3 (see materials and 
methods for treatment concentrations).  (B) Confocal image (20x) demonstrating CNTF-
induced process outgrowth after 3 days in TH-MYCN tumor cells stained for 3A10, a 
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neurofilament associated antigen.  Image brightness enhanced to highlight cell processes.  





Figure 2-2: CNTF effects are time and concentration dependent   
(A) CNTF (closed circles) significantly increases process outgrowth and (B) inhibits 
proliferation over control (open circles) after 3 days in culture (p < 0.0001, ANOVA, 
n=4).  (C) CNTF treatment has no effect on total cell number over the 3 day culture 
period.  (D) CNTF-induced process outgrowth (p < 0.01, ANOVA, n=4) and (E) decrease 
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in proliferation (p < 0.001, ANOVA, n=4) is concentration dependent at 3 days ex vivo.  
EC50 for both effects is ~ 0.4 ng/mL.  (F) There is no concentration-dependent effect of 










Figure 2-3: CNTF promotes TH-MYCN tumor cells that are actively dividing to 
withdraw from the cell cycle   
(A) Experimental design.  On day 1, tumor cells were plated in the presence of 
bromodeoxyuridine (BrdU) and treated with or without CNTF.  BrdU was washed out 
and fresh media and CNTF were added 24 hours later.  Tumor cells were fixed and 
stained for BrdU and Ki67 after another 48 hours in culture.  A similar number of 
untreated (B) and CNTF-treated (D) tumor cells are dividing at 1 day in culture indicated 
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by incorporation of BrdU.  At the 4 day time point a difference in proliferation is 
observed between untreated (C) and CNTF-treated (E) tumor cells, indicated by Ki67 
staining.  A number of CNTF treated tumor cells withdraw from the cell cycle shown by 
staining for BrdU, but not Ki67 (arrows in D and E), while the majority of untreated cells 
remain dividing at both time points.  Scale bar = 10m.  (F) Quantification of the 
percentage of BrdU cells that stain positive for Ki67 shows a significant decrease in Ki67 










Figure 2-4: Ciliary neurotrophic factor receptor alpha (CNTFR) expression in 
TH-MYCN tumor cells in vitro and in vivo  
(A) Confocal image (60x) of cultured TH-MYCN tumor cells stained for CNTFR and 
TH.  Scale bar = 10m.  (B) Quantification of CNTFR expression in acutely isolated 
cultured tumor cells and tumor cells treated with or without CNTF for 3 days in vitro.  
CNTF treatment has no effect on CNTFR expression. (C) Confocal image (60x) of a 
tumor section stained for ciliary neurotrophic factor receptor alpha (CNTFR
tyrosine hydroxylase (TH, green).  Similar to cultured tumor cells, tumor cells abundantly 
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express the CNTF receptor in vivo, while few cells express TH.  Scale bar = 10m.  (D) 
mRNA expression of CNTFR in superior cervical ganglion (SCG) and tumor tissue. 
CNTFR is expressed in tumor tissue at levels equivalent to that of normal sympathetic 
tissue. (E) Confocal image (20x) of a tumor section stained for Ki67 (red) and tyrosine 
hydroxylase (TH, green) isolated from a 35-day old homozygous TH-MYCN mouse.  
Scale bar = 100m.  (F) Confocal image (60x) shows abundant proliferation, indicated by 
Ki67 staining, with isolated non-proliferating TH-expressing tumor cells scattered 















Figure 2-5: NHO1S cells differentiate in response to CNTF in vitro and CNTF 
treatment attenuates NHO1S tumor cell growth in vivo   
(A-B) Similar to primary TH-MYCN tumor cells, NHO1S cells abundantly express 
CNTFR (red stain in A) and Ki67 (red stain in B), while TH expression is more limited 
(green stain in A and B).  (C-E) Like primary TH-MYCN tumor cells, NHO1S cells 
differentiate in response to in vitro CNTF treatment (p < 0.01, Student’s t-test, n=4).  
Scale bar = 100m and applies to all images.  (F) Intraperitoneal injection of CNTF (0.2 
mg/kg daily, black squares) attenuates subcutaneous tumor growth compared to saline 
injected mice (black circles) as measured by change in fold tumor size over the course of 
the experiment (p < 0.01, ANOVA, n=6).  (G) Confirming CNTF was biologically active 
in vivo, CNTF treated mice lost an average of 15% of their starting weight over the 
course of the experiment (p < 0.0001, ANOVA, n=6).  Error bars = SEM.
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Neuroblastoma arises from sympathoadrenal progenitors of the neural crest.  Expression 
of the neurotrophin receptor TrkB and its ligand, brain-derived neurotrophic factor 
(BDNF), is correlated with poor prognosis.  Although activated TrkB signaling promotes 
a more aggressive phenotype in established neuroblastoma cell lines, whether TrkB 
signaling is sufficient to transform neural crest derived cells has not been investigated.  
To address the role of TrkB signaling in malignant transformation, we removed two 
immunoglobulin-like domains from the extracellular domain of the full length rat TrkB 
receptor. This construct (termed ΔIgTrkB) activates phosphorylated Erk1/2 in the 
absence of the TrkB ligand BDNF.  In the pheochromocytoma- derived cell line PC12, 
ΔIgTrkB promotes differentiation by stimulating process outgrowth; however, in the rat 
neural crest derived cell line NCM-1, ΔIgTrkB signaling produces a markedly 
transformed phenotype characterized by increased proliferation, anchorage-independent 
cell growth, anoikis resistance, and matrix invasion.  Furthermore, expression of 
ΔIgTrkB leads to upregulation of many transcripts encoding cancer-associated genes 
including cyclind1, twist1, and hgf, as well as downregulation of tumor suppressors such 
as pten, and rb1.  In addition, ΔIgTrkB NCM-1 cells show a 21-fold increase in mRNA 
for MYCN, the most common genetic marker for a poor prognosis in neuroblastoma.  
When injected into NOD SCID mice, control NCM-1 cells fail to grow while ΔIgTrkB 
NCM-1 cells form rapidly growing and invasive tumors necessitating euthanasia of all 
mice by 15 days post injection.  In summary, these results indicate that activated TrkB 
signaling is sufficient to promote the formation of a highly malignant phenotype in 
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neural crest derived cells. 
 
Introduction 
Neuroblastoma, a pediatric malignancy arising from sympathoadrenal precursors from 
the neural crest (Hoehner et al., 1996), is a cancer typified by its heterogeneity of disease.  
Disease course in neuroblastoma can range anywhere from patients presenting with 
metastatic disease that will spontaneously regress with support treatment alone (stage 
4S), to localized favorable tumors, to cases of aggressive neuroblastoma, in which 
children will often relapse following treatment despite the most intensive chemo- and 
adjuvant therapy (Maris et al., 2007). 
 
This heterogeneity in disease course is correlated with a number of different 
factors including Trk receptor expression (Brodeur, 2003).  Trk receptors are important 
in normal sympathetic development; for example, TrkA, the high affinity receptor for 
nerve growth factor (NGF), promotes target-dependent survival of sympathetic neurons 
by preventing programmed cell death (Miller and Kaplan, 2001; Reichardt, 2006). 
Following this model of development, neuroblastoma tumors that express TrkA have a 
favorable prognosis (Nakagawara, 1998).  In contrast, many MYCN amplified, poor 
prognosis neuroblastomas express TrkB, resulting in tumors that are often highly 
aggressive and eventually fatal (Schramm et al., 2005).  There is also a developmental 
basis for this:  TrkB is transiently expressed in sympathetic progenitors prior to the onset 
of TrkA expression (Straub et al., 2007), and when stimulated with BDNF, the TrkB 
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expressing cells proliferate in cell culture (Reiff et al.; Straub et al., 2007) and in vivo 
(Straub and Nishi, unpublished observations). 
 
An important question is whether TrkB expression is a marker of poor prognosis, 
or whether active TrkB signaling is directly responsible for the aggressive nature of poor 
prognosis neuroblastoma. Supporting a causal role for TrkB signaling, concomitant 
expression of full length TrkB and BDNF leads to autocrine signaling enhancing tumor 
cell survival and invasiveness (Matsumoto et al., 1995).  Conversely, a truncated TrkB 
isoform lacking the tyrosine kinase domain is commonly expressed in more benign and 
differentiated tumors such as ganglioneuroblastomas (Brodeur et al., 1997).  
Furthermore, treatment of TrkB-expressing SMS-KCN neuroblastoma cells with BDNF 
enhances cell survival in serum free media (Nakagawara et al., 1994).  Similarly BDNF 
treatment of SH-SY5Y cells either transfected with TrkB or induced to express TrkB by 
retinoic acid have enhanced survival in conditions of limited growth factors (Matsumoto 
et al., 1995; Kim et al., 1999), increased resistance to chemotherapeutics (Scala et al., 
1996; Ho et al., 2002; Jaboin et al., 2002), increased production of angiogenic factors 
(Eggert et al., 2002; Nakamura et al., 2006), and enhanced invasion (Matsumoto et al., 
1995).  Therefore, TrkB signaling contributes to the aggressiveness of poor prognosis 
neuroblastoma, but it is still unknown whether TrkB signaling alone can transform cells 
of the neural crest lineage. 
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To determine if constitutively active TrkB signaling is sufficient to transform 
cells, we created a mutant form of the TrkB receptor by removal of two immunoglobulin-
like ligand binding domains.  We stably transfected this construct into the neural crest-
derived cell line NCM-1 to investigate its transforming capacity.  Constitutive TrkB 
signaling proved to be highly transforming in NCM-1 cells in vitro, and strongly 
tumorigenic in vivo.  Our results suggest aberrant TrkB signaling alone is sufficient to 




Removal of two immunoglobulin-like domains renders TrkB constitutively active   
To better understand the role of TrkB signaling in neuroblastoma pathogenesis we 
created a constitutively active form of the TrkB receptor.  Previous studies have shown 
the TrkA tyrosine kinase receptor can be rendered constitutively active by removal of the 
two immunoglobulin-like (Ig-like) domains in the extracellular region of the receptor 
(Arevalo et al., 2000).  Therefore, we created this construct (ΔIgTrkB; Fig. 3-1) and 
stably transfected HEK293 cells.  Additionally, a separate stably transfected HEK293 
line was created by transfection with a wild type (WT) TrkB receptor construct.  
Expression of the receptor in both TrkB expressing cell lines was confirmed, with 
ΔIgTrkB displaying a lower molecular weight than WT TrkB (Fig. 3-2A).  As expected, 
a marked increase of phosphorylated Erk 1/2 was observed only when WT TrkB 
HEK293 cells were treated with BDNF.  In contrast, elevated p-Erk 1/2 was observed in 
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both BDNF treated and untreated ΔIgTrkB HEK293 cells (Fig. 3-2A), albeit at 
significantly lower levels when compared to the BDNF-stimulated WT TrkB (Fig. 3-2B).  
Therefore, we tested whether this level of constitutive signaling by ΔIgTrkB was 
sufficient to promote downstream biological effects. 
 
ΔIgTrkB promotes neurite outgrowth in PC12 cells 
PC12 cells are a well-known model of nerve growth factor (NGF) induced neuronal 
differentiation via TrkA (Greene and Tischler, 1976; Kaplan et al., 1991), and TrkB 
transfected PC12 cells differentiate in response to BDNF (Jian et al., 1996).  PC12 cells 
were transiently transfected with ΔIgTrkB or GFP control construct, and two days later 
treated with or without 7sNGF (1µg/mL).  After 6 days, cells were fixed and stained for 
either TrkB or GFP to identify transfected cells.  Cells transfected with ΔIgTrkB had a 6-
fold increase in the number of neurite bearing cells over GFP transfected cells in the 
absence of NGF (Fig. 3-3A-C).  ΔIgTrkB-induced neurite outgrowth is equivalent to that 
of NGF through TrkA, as there was no difference in the number of neurite bearing cells 
between ΔIgTrkB or GFP transfected cells in the presence of NGF (Fig. 3-3D). 
 
ΔIgTrkB enhances proliferation in the neural crest derived cell line NCM-1 
NCM-1 is an immortalized, multipotent cell line with the ability to generate 
sympathoadrenal precursors (Lo et al., 1991).  To determine if constitutive TrkB 
signaling promotes proliferation or differentiation in NCM-1 cells, we transfected cells 
with ΔIgTrkB (Fig. 3-S2).  Stable ΔIgTrkB NCM-1 transfectants had a morphology 
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marked by more rounded cell bodies compared with the bipolar morphology of non-
transfected NCM-1 cells (Fig. 3-4A-F).  Furthermore, ΔIgTrkB NCM-1 cells grew to 
confluency more quickly than WT NCM-1 cells (Fig. 3-4A-F). 
 
In order to quantify the apparent increase in proliferation, cells were counted 
using the vital fluorescent dye calcein AM (Saulnier Sholler et al., 2006).  We noted a 
2.5-fold increase in cell number after 4 days in ΔIgTrkB NCM-1 cells compared with 
WT NCM-1 cells (p < 0.0001, Fig. 3-4I).  Further supporting enhanced proliferation, 
western blot analysis for phosphorylated histone H3, a protein preferentially expressed in 
dividing cells, demonstrated in IgTrkB NCM-1 cells a 1.5-fold increase compared with 
WT cells (p < 0.05, Fig. 3-4G-H).  To confirm that this phenotype did not arise from a 
random insertion of our construct disrupting a tumor suppressor, five additional parent 
lines were established.  All showed a significant increase in cell number after 4 days in 
vitro (Fig. 3-S3, p < 0.001).  Additionally, treatment with the pan-Trk kinase inhibitor 
K252a abolished ΔIgTrkB-mediated proliferation, resulting in calcein AM fluorescence 
equivalent to WT NCM-1 cells (Fig. 3-4J).  This demonstrated that TrkB kinase activity 
is required for the observed enhanced proliferation.  Therefore, constitutive signaling 
through ΔIgTrkB promotes a higher rate of proliferation in the neural crest-derived 
NCM-1 cell line. 
 
ΔIgTrkB transforms NCM-1 cells 
Although ΔIgTrkB signaling increases the rate of growth of NCM-1 cells, enhanced 
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proliferation alone is not sufficient to consider a cell transformed.  For example, healthy 
cells require attachment to a surface to divide, and the loss of this requirement in 
transformed cells is known as anchorage-independent cell growth.  To determine if 
ΔIgTrkB expression confers anchorage independent cell growth, cells were cultured 
suspended in soft agar.  After one week, there was a 25-fold increase in colony formation 
in ΔIgTrkB transfected cells (p < 0.001, Fig. 3-5A-C). 
 
Normally, when cells grown in culture detach from the culture surface they 
undergo anoikis, or detachment-induced apoptosis; however, cancer cells escape anoikis.  
To determine if ΔIgTrkB allows NCM-1 cells to become anoikis resistant, the number of 
live cells in the medium collected from transfected and untransfected cells was 
quantified.  We observed a 4-fold increase in the number of live cells in the media from 
ΔIgTrkB NCM-1 cultures compared with WT NCM-1 (p < 0.05, Fig. 3-5D), indicating 
ΔIgTrkB promotes anoikis resistance in NCM-1 cells. 
 
Another important characteristic of malignant transformation is the ability of cells 
to migrate to and invade surrounding tissues and blood vessels.  To investigate whether 
ΔIgTrkB expression enhances migration and invasion we used a radial migration assay 
known as ‘the donut assay’ (McKenzie et al., 2011).  In this assay, cells are limited to a 
restricted area by silicone donut.  Following donut removal, the number of cells 
migrating radially from the confined area are quantified.  Neural crest cells are 
intrinsically migratory, as during development they must migrate from the neural tube to 
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their final locations throughout the body.  In light of this, we did not find any significant 
difference in the total number of migrating cells outside the originally confined area after 
24 hours (Fig. 3-6A-C, E-G, J).  However, there was a significant increase in the area 
within which migrated cells could be found, indicating that in our assay ΔIgTrkB NCM-1 
cells migrated farther compared with WT NCM-1 cells (p < 0.0001, Fig. 3-6D, H-I). 
 
Although neural crest cells are intrinsically migratory, they are not intrinsically 
invasive.  Invasion requires the ability of cells to degrade extracellular matrix in order to 
migrate.  To investigate invasion, a layer of matrigel was overlaid on the cells in a new 
set of experiments.  Addition of matrigel led to a reduction in the number of cells that 
traveled outside the originally confined area for both cell types (Fig. 3-6J vs. 3-6T).  We 
observed that ΔIgTrkB NCM-1 cells had an enhanced ability to invade extracellular 
matrix that was marked by a 2.5-fold increase in the number of invading cells after 24 
hours (p < 0.05, Fig. 3-6K-M, O-Q, T).  Furthermore, ΔIgTrkB NCM-1 cells invaded 
across a greater distance into the matrigel as indicated by a 2.5-fold increase in total area 
invaded by ΔIgTrkB NCM-1 cells compared with WT (p < 0.05, Fig. 3-6N, R, S). 
 
ΔIgTrkB enhances cancer related gene expression in NCM-1 cells 
To identify genes contributing to the transformed phenotype in ΔIgTrkB NCM-1 cells, 
we analyzed transcripts using a targeted qPCR array for cancer pathway genes.  This 
analysis revealed that expression of ΔIgTrkB increases transcript levels for a number of 
cancer promoting genes (Table 3-1), as well as decreases the expression of tumor 
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suppressor genes (Table 3-2).  Consistent with the enhanced proliferation of ΔIgTrkB 
NCM-1 cells compared with WT cells, we detected a 436-fold increase in transcripts 
levels (p < 0.0001) as well as significantly enhanced protein levels (p < 0.05, Fig. 3-S4) 
for the cell cycle regulatory gene cyclind1.  Furthermore, upregulation of twist1 (39-fold, 
p < 0.0001) and hepatocyte growth factor (hgf, 29-fold, p < 0.0001), two genes known to 
play important roles in promoting invasion and metastasis (Li et al.; Hecht et al., 2005), is 
consistent with the enhanced invasive capacity of ΔIgTrkB NCM-1 cells.  Moreover, 
expression of ΔIgTrkB in NCM-1 cells significantly downregulates expression of the 
tumor suppressors pten (-1.71-fold, p<0.001) and rb1 (-1.77-fold, p<0.001).  Therefore, 
mRNA expression in ΔIgTrkB NCM-1 cells is consistent with the highly transformed 
phenotype of the cells. 
 
c-Met inhibition abolishes enhanced proliferation in ΔIgTrkB NCM-1 cells 
Previous work has implicated the hepatocyte growth factor (HGF) / c-Met signaling 
pathway in promoting neuroblastoma cell invasiveness (Hecht et al., 2005). In ΔIgTrkB 
NCM-1 cells hgf levels were upregulated 29-fold.  Additionally, c-Met was also 
upregulated 1.5-fold (p < 0.0001), suggesting that this pathway may be important in the 
transformed phenotype mediated by constitutive TrkB signaling.  Furthermore, while 
K252a was first characterized as a pan-Trk kinase inhibitor, it has also been shown to 
inhibit a number of other tyrosine kinases including c-Met (Morotti et al., 2002).  This 
suggested that our K252a proliferation inhibition results may have been due to c-Met 
inhibition.  In order to determine if the c-Met signaling pathway mediates ΔIgTrkB-
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induced proliferation, WT and ΔIgTrkB NCM-1 cells were grown in the specific c-Met 
inhibitor SU11274 and proliferation was assessed.  Treatment with SU11274 (1 µM) 
abolished the increased proliferation of ΔIgTrkB NCM-1 cells, resulting in a 4 day 
growth curve that mirrored that of WT NCM-1 cells treated with, or without inhibitor 
(Fig. 3-7).  Treatment with vehicle (DMSO) alone had no effect on the enhanced 
proliferation of ΔIgTrkB NCM-1 cells (Fig. 3-7, p < 0.0001), verifying that this effect 
was specific to the inhibitor.  These results show that c-Met signaling is required for the 
enhanced proliferation of IgTrkB NCM-1 cells. 
 
ΔIgTrkB upregulates expression of the poor prognosis marker mycn in NCM-1 cells 
To determine if the transformation of NCM-1 cells by ΔIgTrkB influences the expression 
of mycn, a marker of poor prognosis in neuroblastoma that was not included in the cancer 
pathway array, we compared transcript levels in WT and ΔIgTrkB NCM-1 cells by 
qPCR.  We found a 21-fold increase in mycn levels in ΔIgTrkB NCM-1 cells compared 
with WT NCM-1 cells (p < 0.01, Table 3-1).  Therefore, aberrant TrkB signaling in the 
neural crest derived NCM-1 cell line is sufficient to upregulate expression of the 
neuroblastoma poor prognosis marker MYCN. 
 
ΔIgTrkB NCM-1 cells form rapidly growing and aggressive tumors in vivo 
To determine if ΔIgTrkB expression would enhance the ability of NCM-1 cells to form 
tumors in vivo, NOD-SCID mice were injected subcutaneously with 1 million ΔIgTrkB 
or WT NCM-1 cells suspended in matrigel.  One week following NCM-1 cell injection, 
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tumors became palpable in mice injected with ΔIgTrkB cells (Fig. 3-8A, p < 0.01), and 
all ΔIgTrkB NCM-1 injected mice were sacrificed by 15 days post-injection due to tumor 
burden (Fig. 3-8B, p< 0.01).  WT NCM-1 injected mice remained tumor free throughout 
the experiment (Fig. 3-8).  Monitoring tumor size daily, ΔIgTrkB NCM-1 tumors grew 
rapidly, measuring an estimated 8 cm3 by 2 weeks after injection, while WT NCM-1 
cells failed to grow (Fig. 3-8C, p < 0.0001).  Upon removal, ΔIgTrkB NCM-1 cell tumors 
were large and vascularized with an average wet weight of 4.5 grams (Fig. 3-8E-F). 
ΔIgTrkB tumors grew at a rapid pace and were also highly invasive, invading the 
vertebrae and compressing the spine in one mouse.  This resulted in bilateral hind limb 
paralysis by 10 days following injection (Fig. 3-8G-H).   Tumor tissue showed a 
histology that consisted of many closely packed cells with scant cytoplasm and little 
extracellular stroma, reminiscent of aggressive, poor prognosis neuroblastoma (Fig. 3-
8D).  Furthermore, a separate injection of only 100 cells formed tumors in 3/3 mice 
within 21 days, demonstrating that ΔIgTrkB NCM-1 cells are highly tumorigenic.  
Therefore, constitutive TrkB signaling is sufficient to transform the neural crest derived 
cell line NCM-1 into highly aggressive tumor cells in vivo. 
 
Discussion 
We provide evidence that constitutive TrkB signaling is sufficient to transform a neural 
crest cell line into a carcinogenic phenotype marked by enhanced proliferation, 
anchorage independent cell growth, anoikis resistance, migration and invasion, and 
tumorigenesis.  Furthermore, we noted transcriptional deregulation as a consequence of 
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aberrant TrkB signaling, such as upregulation of MYCN, a gene whose amplification is 
significantly correlated with both the expression of TrkB/BDNF in neuroblastoma, as 
well as a more aggressive tumor phenotype and poor prognosis.  Taken together, our data 
suggest that aberrant TrkB signaling in the developing sympathoadrenal lineage may be 
sufficient to promote neuroblastoma formation. 
 
Although Trk receptors are now known to be the high affinity receptors for the 
neurotrophin family of growth factors, the first Trk receptor (TrkA) was discovered as an 
oncogene.  Named the “tropomyosin-receptor kinase” (Trk), the gene was isolated from a 
colon carcinoma, and resulted from the fusion of a truncated tropomyosin and the 
tyrosine kinase domain of TrkA that rendered the kinase constitutively active (Martin-
Zanca et al., 1986).  Subsequently, the TrkB receptor was discovered and found to be the 
high affinity receptor for BDNF, and when co-expressed in 3T3 fibroblasts with BDNF, 
receptor activation promoted proliferation and anchorage-independent cell growth (Glass 
et al., 1991; Klein et al., 1991).  In epithelial cells, TrkB has been shown to promote 
anoikis resistance by conferring cells with the ability to grow in suspension (Douma et 
al., 2004), whereas TrkB signaling enhances invasion in a number of cell lines including 
neuroblastoma (Matsumoto et al., 1995; Hecht et al., 2005; Cimmino et al., 2009), colon 
cancer (Yu et al., 2006), head and neck squamous cell carcinoma (Kupferman et al., 
2010), non-small cell lung cancer (Zhang et al., 2010), and epithelial (Geiger and Peeper, 
2007).  TrkB signaling in vivo promotes tumor growth in neuroblastoma (Eggert et al., 
2002), epithelial (Douma et al., 2004), and transitional cell carcinoma (Huang et al., 
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2010).  However, none of these studies determined whether TrkB signaling in neural 
crest-derived cells is sufficient to promote an aggressive, fully transformed phenotype. 
 
Transformation of rat NCM-1 cells by ΔIgTrkB activates the expression of genes 
also seen in poor prognosis neuroblastoma including cyclind1, twist1, hgf, and mycn.  
CYCLIND1 is known to be selectively amplified in poor prognosis neuroblastoma tumors 
(Molenaar et al., 2011), and this heightened expression is not simply a general 
characteristic of any cancer, but is more elevated in neuroblastoma compared to many 
other tumors (Molenaar et al., 2011).  Further supporting ΔIgTrkB NCM-1 cells as a 
model for poor prognosis neuroblastoma, TWIST1 has been shown to be expressed in 
100% (7/7) of MYCN amplified tumors, but only 11% (2/18) of non-MYCN amplified 
tumors (Valsesia-Wittmann et al., 2004).  In MYCN amplified neuroblastoma cell lines, 
TWIST1 expression ranged from 16-164 fold that of non-MYCN amplified lines 
(Valsesia-Wittmann et al., 2004), consistent with the 39-fold increase in twist1 
expression we observed in ΔIgTrkB NCM-1 cells.  This suggests a specific cooperation 
of TWIST1 and MYCN in neuroblastoma, TWIST1 inhibits expression of the tumor 
suppressor P53 (Valsesia-Wittmann et al., 2004), which allows MYCN-amplified tumors, 
and in the case of our study, ΔIgTrkB NCM-1 cells, to escape P53-dependent apoptosis.  
In this study we noted a 29-fold upregulation of hgf, and a 1.5-fold upregulation of the 
HGF receptor c-met in ΔIgTrkB NCM-1 cells.  Although increased c-Met signaling is a 
common occurrence in many types of cancer (Liu et al., 1992; Furukawa et al., 1995; 
Ramirez et al., 2000; Tokunou et al., 2001; Lengyel et al., 2005), the only other study to 
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demonstrate TrkB-mediated upregulation of c-Met signaling was in neuroblastoma cells, 
where TrkB expression led to 5- to 10-fold increases in HGF, and 40- to 400-fold 
increases in c-Met mRNA levels.  This same study found TrkB-expressing primary 
neuroblastoma tumor samples to have coordinated expression of HGF and c-Met (Hecht 
et al., 2005). 
 
  ΔIgTrkB NCM-1 cells display an enhanced ability to form rapidly growing and 
invasive tumors, compared to oncogenes expressed in other cell lines.  NCM-1 cells were 
isolated from rat embryos and immortalized by transduction with a v-myc-containing 
replication-deficient retrovirus (Lo et al., 1991).  Although v-myc expression itself can 
be transforming (Ramsay et al., 1990), this is not the case in NCM-1 cells because of 
their ability to differentiate (Lo et al., 1991), and because they do not grow in soft agar, 
or form tumors in vivo.  We observed that the addition of constitutive TrkB signaling 
resulted in dramatically transformed cells that form large invasive tumors.  Similar in 
vivo tumor growth was seen in a v-myc immortalized rat fibroblast cell line expressing 
oncogenic BCR-ABL (Lugo and Witte, 1989), however this study injected 50% more 
cells to initiate tumorigenesis (1.5 million as opposed to 1 million injected here).  In 
another study, expression of the oncogene BCL2 led to in vivo tumorigenesis in a rat L6 
myoblast cell line expressing v-myc, but tumors formed only after 10 weeks (Screaton et 
al., 1997).  Recently, Schulte et. al. (2012) found that JoMa1 neural crest progenitor cells 
(maintained in an undifferentiated state by inducible c-myc expression) can be 
transformed by an oncogenic variant of the ALKF1174L, and in 2 out of 6 mice were able 
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to form tumors in vivo that were lethal to the mouse by 48 days following injection of 20 
million cells (Schulte et al., 2012).  Thus, ΔIgTrkB is considerably more oncogenic in 
vivo than ALKF1174L.  ΔIgTrkB NCM-1 tumors were also highly invasive.  In one 
mouse, tumor cell invasion of the spine, caused spinal cord compression and bilateral 
paralysis.  This observation is reminiscent of cases of human neuroblastoma, where 
cancer can extend into the spinal foramina causing nerve root and spinal cord 
compression in patients with paraspinal tumors (Plantaz et al., 1996; De Bernardi et al., 
2001; De Bernardi et al., 2005).  In total, 5% of all neuroblastoma patients present with 
signs related to cord impingement (Plantaz et al., 1996; De Bernardi et al., 2001). 
 
The highly aggressive behavior observed in ΔIgTrkB NCM-1 cells is not likely 
due solely to upregulation of MYCN.  Because MYCN amplification is the most consistent 
genetic alteration seen in poor prognosis neuroblastoma (Seeger et al., 1985), it has been 
hypothesized that MYCN overexpression is largely responsible for the aggressive 
phenotype of these tumors.  The 21- fold upregulation of mycn mRNA observed in 
ΔIgTrkB NCM-1 cells is consistent with the increased mRNA expression observed in 
MYCN-amplified neuroblastoma tumors and cell lines, which has been observed to range 
anywhere from 20- to 80-fold (Schwab et al., 1984).  Furthermore, while MYCN 
amplification is present in only 25% of neuroblastomas (Brodeur et al., 1986), 70% of 
these tumors express TrkB and BDNF (Nakagawara et al., 1994).  Therefore, in the 
proper developmental context, active TrkB signaling may drive MYCN amplification in 
MYCN/TrkB/BDNF expressing neuroblastomas.  While other studies suggest MYCN 
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overexpression itself is sufficient to drive neuroblastoma formation, the subsequent 
tumors formed are slower growing and more spatially-confined than the tumors we 
observed from ΔIgTrkB NCM-1 cells.  For example, in the TH-MYCN transgenic mouse, 
targeted expression of MYCN to the neural crest lineage by driving expression with the 
tyrosine hydroxylase promoter is tumorigenic (Weiss et al., 1997).  However, unlike the 
human form of the disease where TrkB and BDNF are highly expressed in the majority of 
MYCN amplified tumors, TH-MYCN tumors highly express BDNF, but lack TrkB 
expression (DeWitt and Nishi, unpublished data).  Also, MYCN amplification is unlikely 
to be the initiating event in human neuroblastoma, as amplification of this gene is not 
known to occur in normal mammalian cells (Tlsty, 1990; Wright et al., 1990; Fischer et 
al., 2012).  In addition, JoMa1 neural crest cells overexpressing MYCN form highly 
variable, slow growing tumors with mice surviving anywhere from 43-123 days (Schulte 
et al., 2012).  Thus our results suggest that TrkB upregulates MYCN in parallel with 
additional pathways that contribute to a highly aggressive, carcinogenic phenotype.  This 
underscores the importance of the development of therapies targeting TrkB signaling, 
such as lestaurtinib (CEP-701) (Minturn et al., 2011). 
 
Materials and methods 
Constructs:  Using a full-length rat trkb (WT trkb) construct generously provided by Dr. 
Moses Chao, New York University, NY, NY, we used site-directed mutagenesis to 
convert a single base at base pair 1814 into a pst1 site.   Both Ig-like domains could then 
be removed by pst1 (New England Biolabs, Ipswich, MA) digestion due to another pst1 
 98 
site at base pair 1233.  For HEK293 experiments ΔIgtrkb and WT trkb were cloned into 
pcDNA3.1 (Invitrogen, San Diego, CA).  For PC12 experiments ΔIgtrkb was cloned into 
an inducible vector (pTRE-tight) and transfected into an rTTa-expressing PC12 Tet-on 
cell line (Clontech, Mountain View, CA).  For NCM-1 experiments ΔIgtrkb was cloned 
into a piggyBAC transposon-transposase vector (pmhyGENIE-3) containing a DsRed tag 
and hygromycin selection gene (Urschitz et al., 2010).  NCM-1 cells were transfected 
with a GFP-expressing control piggyBAC vector (pmGENIE-3) to establish a control cell 
line for in vivo experiments. 
 
Cell Culture:  Cells were grown at 37°C in 5% CO2.  HEK293 and NCM-1 cells were 
maintained in 10% (v/v) fetal bovine serum, 20 U/mL penicillin, 20 mg/mL 
streptomycin, 2mM L-glutamine, and 6 mg/mL glucose in modified L15CO2 (Mains and 
Patterson, 1973).  Serum for PC12 cells was 5% fetal bovine serum and 5% heat-
inactivated horse serum. 
 
Transfections:  HEK293 and PC12 cells were transfected using JetPEI (Polyplus 
transfection, Illkirch, France).  Stably-transfected HEK293 cells were established by 
G418 (Sigma, St. Louis, MO) selection.  NCM-1 cells were transfected using X-
tremeGENE 9 (Roche, Indianapolis, IN) and stable cells were established by hygromycin 
(Sigma) selection. 
  
Western blotting:  Cells were seeded at 250,000 per well in 6-well plates.  For HEK293 
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experiments cells were serum-starved for 24 hours, treated with, or without BDNF 
(100ng/mL, R&D Systems) for 1 hour and then collected for SDS PAGE by direct lysis 
into 100 µL of 1x SDS sample buffer + 5% β−Mercaptoethanol (βMe).  Samples were 
run on an 8% polyacrylamide gel and then transferred to a nitrocellulose membrane 
(Osmonics, Inc., Minnetonka, MN) overnight at 4°C at 30 volts (Hoefer Scientific 
Instruments, San Francisco, CA).  Blots were incubated with primary antibodies 
overnight at 4°C, washed 4x for 10 minutes, and then incubated in appropriate secondary 
antibodies for 1 hour at room temperature.  Primary antibodies used were:  goat anti-
TrkB (1:1000, R&D Systems); rabbit anti-p-Erk1/2 (1:500, Cell Signaling, Boston, MA); 
goat anti-β actin (1:1000, Santa Cruz, Santa Cruz, CA); rabbit anti-Phospho-Histone H3 
(1:500, Cell Signaling); and mouse anti-Cyclin D1 (1:1000; Cell Signaling).  Secondary 
antibodies used were donkey anti-goat 700 (Rockland, Gilbertsville, PA); donkey anti-
rabbit 800 (Rockland); and donkey anti-mouse 800 (Rockland) all at 1:10 000.  Blots 
were analyzed with an Odyssey Infrared Imager (LI-COR Biosciences, Lincoln, NE).  
 
PC12 neurite outgrowth:  PC12 cells were plated on poly-D-lysine (0.5 mg/mL, Sigma) 
and laminin (0.02 mg/mL, purified in the Nishi lab from EHS tumors grown 
subcutaneously in C57Bl6 mice) coated coverslips at 50,000 cells per well.  The day after 
plating, cells were transfected with either an inducible GFP or the inducible ΔIgtrkb 
construct and allowed to recover for 48 hrs prior to treatment with doxycline (1 µg/mL, 
Sigma) and 7s NGF (1 µg/mL, Alomone, Jerusalem, Israel). Coverslips were fixed 30 
min in Zamboni's fixative (4% (w/v) paraformaldehyde, 15% (v/v) picric acid in 0.1 M 
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sodium phosphate buffer, pH 7.4) and processed for immunocytochemistry as previously 
described (Hruska and Nishi, 2007).  Primary antibodies were:  goat anti-TrkB (1:1000, 
R&D Systems); chicken anti-GFP (1:1000, Aves, Tigard, OR).  Secondary antibodies 
were:  donkey anti-goat alexa 488 (1:1000, Invitrogen) and goat anti-chicken alexa 488 
(1:1000, Invitrogen).  A Nikon Eclipse E800 microscope connected to a computer 
equipped with StereoInvestigator software (MBF Bioscience, Williston, VT) was used to 
count neurite-positive PC12 cells.  A neurite was defined as a process with a length at 
least twice the cell’s soma size. 
 
Calcein AM:  NCM-1 cells were plated on poly-D-lysine coated 96 well plates at 200 
cells per well in 100 µL of media and viability was assessed using 2 µM calcein AM 
(Molecular Probes, Eugene, OR) with a FLUOstar Galaxy (BMG, Cary, NC) fluorescent 
microplate reader.  Each condition was replicated in a minimum of 8 wells on the same 
plate.  For K252a (Merck, Darmstedt, Germany) and c-Met inhibitor (SU11274, Merck) 
treatments, inhibitors (50 nM and 1 µm, respectively) were added at the time of plating. 
 
Soft agar assay:  6-well plates were coated with 0.5% agar (Affymetrix, Santa Clara, CA) 
in growth medium.  After the base layer had solidified, NCM-1 cells suspended in 0.35% 
agar were plated on top of the base layer at 1000 cells per well.  Cells were fed by adding 
0.5 mL of media to the top of each well every 3 days.  Colony number was quantified 
after 7 days. 
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Anoikis assay:  To quantify anoikis, medium was collected 3 days after cultures achieved 
confluence and the number of live cells growing in the media was quantified by trypan 
blue (0.08%, Sigma) exclusion and a hemocytometer. 
 
Migration and invasion:  The ‘donut assay’ for migration and invasion was used as 
described (McKenzie et al., 2011).  Cells (10,000) were plated on poly-D-lysine- and 
laminin-coated coverslips in a 10 µL volume. Initial images were acquired through a 2X 
PlanApo objective on a Nikon Eclipse TE-2000E inverted microscope.  A second set of 
images acquired after 24 hours were compared and analyzed using the default settings of 
a custom written ImageJ macro (McKenzie et al., 2011).  With the macro, area migrated / 
invaded was quantified by measuring the area between the outer bound of the farthest 
migrating / invading cells after 24 hours and the bound of the cells directly after gasket 
removal. 
 
RNA extraction and qPCR array:  Cells were grown to confluence in 6-well plates, lysed 
directly into TRI Reagent (Molecular Research Center, Cincinnati, OH), and RNA was 
isolated using the manufacturer’s protocol.  RNA quality and genomic DNA 
contamination were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA).  Reverse transcription and Cancer Pathways qPCRarray plate 
(SABiosciences, Valencia, CA) analysis was performed at the VT Cancer Center DNA 
Analysis Facility using a RT2 First Strand kit (SABiosciences, Valencia, CA).  Three 
arrays each testing an independently isolated RNA sample were analyzed for each cell 
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line. Mycn expression transcription levels were evaluated by reverse transcription of 1 µg 
of RNA transcribed to cDNA using (Superscript III, Invitrogen) and subsequent Taqman-
based qPCR (ABI).   
 
In vivo:  Mice were housed in an NIH and AALAC approved animal facility at UVM and 
treated following an approved IACUC protocol.  Cells were injected subcutaneously into 
flanks of NOD-SCID mice at 10
6
 cells per mouse in 200 µL of matrigel (BD 
Biosciences).  Four mice were injected per cell line.  When tumors became palpable, 
tumor growth was quantified initially every other day, and then daily when it became 
apparent TrkB tumors were fast growing.  Tumor volume was estimated from length and 
width measurements by the formula v = 1.58(π/6)(L*W)^(3/2) (Feldman et al., 2009).  To 
examine the lower limits of the tumorigenic potential of ΔIgTrkB NCM-1 cells, 100 cells 
in 200 µL of matrigel were injected into 3 NOD-SCID mice that were then monitored for 
tumor formation. 
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Table 3-1: Tumor promoters upregulated in IgTrkB NCM-1 cells 
IgTrkB and WT NCM-1 cells were grown to confluence in 6 well plates and RNA was 
isolated using TRI Reagent.  Gene expression was determined using a Cancer Pathway 
qPCR array plate (SABiosciences).  Mycn expression (in bold) was determined 
separately by Taqman-based qPCR (ABI).  Data is the average of n=3 RNA samples 
from 3 different wells of a 6 well plate for each cell line.  p-value determined by 

















Symbol Gene Fold 
Regulation 
P-value Description 
ccnd1 Cyclin D1 436.1 0.000069 Promotes cell cycle 
progression 
twist1 Twist homolog 1 
(Drosophila) 







28.86 0.008818 Promotes mitogenesis, 
cell motility, and 
matrix invasion 
ccnd2 Cyclin D2 26.40 0.000137 Promotes cell cycle 
progression 
mycn N-Myc 21.00 0.010000 Marker of aggressive 
neuroblastoma 
fgf2 Fibroblast growth 
factor 2 
19.88 0.001753 Promotes angiogenesis 
angpt1 
 





6.385 0.000792 Mediates multidrug 
resistance 
muc1 Mucin 1, cell 
surface associated 
4.884 0.000030 Inhibits p53-mediated 
apoptosis, and 





4.816 0.000115 Promotes angiogenesis 
serpine1 Serpin peptidase 




type 1), member 1 
4.661 0.000027 Promotes invasion and 
metastasis 
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Table 3-2: Tumor suppressors downregulated in IgTrkB NCM-1 cells 
IgTrkB and WT NCM-1 cells were grown to confluence in 6 well plates and RNA was 
isolated using TRI Reagent.  Gene expression was determined using a Cancer Pathway 
qPCR array plate (SABiosciences).  Data is the average of n=3 RNA samples from 3 
different wells of a 6 well plate for each cell line.  p-value determined by Student’s t-test. 
 
Symbol Gene Fold 
Regulation 
P-value Description 
thbs1 Thrombospondin 1 -2.118 0.000563 Promotes cell 
adhesion 
pik3r1 Phosphoinositide-3-kinase, 
regulatory subunit 1 (alpha) 
-1.913 0.000261 Inhibitor of 
PI3K signaling 
rb1 Retinoblastoma 1 -1.771 0.000464 Inhibits cell 
cycle 
progression 
tgfbr1 Transforming growth factor, 
beta receptor 1 
-1.755 0.001248 Inhibits cell 
growth 
pten Phosphatase and tensin 
homolog 
-1.710 0.000285 Inhibits cell 
proliferation 
bad BCL2-associated agonist of 
cell death 
-1.572 0.004340 Promotes 
apoptosis 
cdkn1a Cyclin-dependent kinase 
inhibitor 1A 







Figure 3-1:  Construction of a constitutively active TrkB receptor by removal of the 
two immunoglobulin-like ligand binding domains 
(a) The 193 amino acid sequence coding for the two Ig-like ligand binding domains 
(shown in grey italics) of the 629 amino acid TrkB protein was removed by restriction 
digest.  (b) The full-length wild type TrkB protein consists of two cysteine-rich domains 
(CRD) surrounding a leucine-rich domain (LRD), two immunoglobulin-like domains 
(IGD), and the intracellular tyrosine kinase domain (TKD).  In the IgTrkB construct the 




Figure 3-2:  IgTrkB is expressed and is constitutively active 
HEK293 cells were stably transfected with either a WT or IgTrkB construct.  Cells were 
then treated with or without BDNF (100 ng/mL) and protein was isolated.  (a) Western 
blot for TrkB and phosphorylated Erk 1/2 demonstrates that IgTrkB is expressed, and 
signals in the absence of the TrkB ligand BDNF.  (b) Quantification of phosphorylated 
Erk 1/2 protein expression reveals a significant increase in phospho Erk 1/2 in IgTrkB 
transfected cells treated with (black bars), or without (white bars) BDNF, compared to 
untreated WT TrkB transfected cells (p < 0.0001, ANOVA, n=3, error bars = SEM) or 
untransfected HEK293 cells.  Constitutive IgTrkB activity is two-fifths that of the WT 






Figure 3-3: IgTrkB promotes process outgrowth in PC12 cells   
Transfected cells were assessed for process outgrowth 6 days following transfection.  (a) 
PC12 cells transfected with GFP have minimal neurite outgrowth, (b) while IgTrkB 
transfection stimulates neurite outgrowth.  (c) Quantification of process outgrowth in 
PC12 cells reveals a 6-fold increase in the number of cells bearing neurites when 
transfected with IgTrkB as opposed to a GFP control plasmid (p < 0.0001, Student’s t-
test, n=3, error bars = SEM).  (d) In the presence of NGF the number of cells bearing 
neurites is equivalent in the two transfection conditions.  Scale bar is equivalent to 25 m 






Figure 3-4: IgTrkB promotes proliferation in the neural crest derived cell line 
NCM-1  
(a-f) Phase contrast images of IgTrkB and WT NCM-1 cell growth in a 12-well plate.  
Times indicated are hours after plating, 100,000 cells plated at time 0.  (g) Calcein AM 
uptake reveals a highly significant increase (p < 0.0001, ANOVA) in growth in IgTrkB 
NCM-1 cells (closed triangles, points represent mean calcein AM fluorescence, n=16, 
error bars = SEM) compared with wild type cells (closed squares) over a 4 day period.  
(h-i) IgTrkB NCM-1 cells also have a two-fold increase in expression of the 
proliferation marker phosphorylated histone H3 (p < 0.05, Student’s t-test, n=3, error bars 
= SEM).  (j) The pan-Trk inhibitor K252a (50 nM) abolishes increased proliferation (p < 
0.0001, ANOVA, n=8, error bars = SEM) in IgTrkB NCM-1 cells (open triangles) 
compared with DMSO treated IgTrkB NCM-1 cells (closed triangles). IgTrkB 
proliferation in the presence of K252a is similar to WT NCM-1 proliferation in the 
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presence of either K252a (open squares) or DMSO (closed squares).  Scale bar is 





Figure 3-5: IgTrkB promotes anchorage-independent cell growth and anoikis 
resistance in NCM-1 cells   
Soft agar assay in 6-well plates.  (a) Wild type NCM-1 cells have little ability to grow in 
soft agar, (b) while IgTrkB NCM-1 cells form numerous colonies.  (c) Quantification of 
colony growth shows a 25-fold increase in colony formation in IgTrkB NCM-1 cells (p 
< 0.001, Student’s t-test, n=6, error bars = SEM).  (d) IgTrkB NCM-1 cells are also 
resistant to detachment-induced apoptosis marked by a significant increase (p < 0.05, 
Student’s t-test, n=4, error bars = SEM) in the number of live cells in suspension as 





Figure 3-6: IgTrkB enhances migration and invasion of NCM-1 cells  
(a-d) Migration of wild type NCM-1 and (e-h) IgTrkB NCM-1 cells.  (i) Quantification 
of migration shows a significant increase in the area migrated (p < 0.0001, Student’s t-
test, n=8, error bars = SEM) in IgTrkB NCM-1 cells (h compared to d), (j) but no 
difference in the total number of cells migrated.  For invasion assay, cells were overlayed 
with matrigel.  (k-n) Matrigel invasion in wild type NCM-1 and (o-r) IgTrkB NCM-1 
cells.  (s) IgTrkB significantly enhances both area invaded (r compared to n), and (t) 
 122 
the total number of invading NCM-1 cells (p < 0.05, Student’s t-test, n=3, error bars = 




Figure 3-7:  c-Met inhibition abolishes IgTrkB -mediated proliferation in NCM-1 
cells 
IgTrkB and WT NCM-1 cell proliferation was quantified over a 4 day time period by 
calcein AM uptake.  Treatment with the c-Met inhibitor SU11274 (1 mM) abolishes 
increased proliferation (p < 0.0001, ANOVA, n=8, error bars = SEM) in IgTrkB NCM-
1 cells (open triangles) compared with DMSO vehicle control treated IgTrkB NCM-1 
cells (closed triangles). IgTrkB proliferation in the presence of the c-Met inhibitor is 
equal to WT NCM-1 proliferation in the presence of either inhibitor (open squares) or 












Figure 3-8: IgTrkB NCM-1 cells form highly aggressive tumors in vivo 
(a) Kaplan-Meier plot of tumor-free survival in NOD-SCID mice subcutaneously injected 
with WT NCM-1 cells (solid line), or IgTrkB NCM-1 cells (dotted line).  No mice 
injected with WT NCM-1 cells formed tumors over the course of the experiment (p < 
0.01, log-rank (Mantel-Cox) test, n=4).  (b) Kaplan-Meier plot of overall survival.  All 
IgTrkB NCM-1 cell-injected mice had to be sacrificed by 15 days after initial cell 
injection due to tumor burden (p < 0.01, log-rank (Mantel-Cox) test, n=4).  (c) Estimated 
tumor volume over the course of the experiment. IgTrkB NCM-1 cell injected mice 
formed rapidly growing tumors starting at 1 week following initial cell injection, with a 
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significant difference in tumor volume versus matrigel plug volume by 11 days (p < 
0.0001, ANOVA, n=4, error bars = SEM).  Removed tumors had an average wet weight 
of 4.5 grams.  (d) Hematoxylin and Eosin staining of tumor tissue reveals densely packed 
cells with scant cytoplasm and absent extracellular stroma reminiscent of poor prognosis 
neuroblastoma.  (e) Example of mouse injected with WT NCM-1 cells, and (f) IgTrkB 
NCM-1 cells (matrigel (e) and tumor (f) are outlined in black).  (g-h) In one mouse, the 
tumor invaded the spinal cord causing bilateral hind limb paralysis.  (g) Normal thoracic 
spinal cord (labeled SC) surrounded by vertebrae, rostral to tumor invasion.  (h) The 
lower thoracic spinal cord (labeled SC) is compressed in the vertebrae by invading tumor 
cells (labeled T). Scale bar in (g) is equivalent to 1 mm and also applies to (h).  Scale bar 
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Figure 3-S1: The pBAC-ΔIgTrkB-dsRED construct 
The ΔIgTrkB gene was cloned into the first multiple cloning site (MCS) of a bicistronic 
construct driven by the CMV-IE Enhancer, chicken β-actin promoter and β-globin intron 
(CAG) promoter that was previously inserted into the recombineering region of an 
Invitrogen pENTR1a vector.  The second MCS of the bicistronic construct after the 
IRES2 sequence contained a dsRed Express2 gene.  Due to restriction enzyme site limits 
the thymidine kinase promoter driven hygromycin gene and polyA was placed in reverse 
orientation between the end of the dsRed Express2 gene and its SV40 polyA site.  The 
pENTR1a vector containing the above described bicistronic construct architecture was 
subsequently inserted into a pmhyGENIE-3 plasmid containing a hyperactive piggyBac 
gene, by Gateway recombineering as described previously (Urschitz et al., 2010).  The 
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pmGENIE-3 plasmid containing a mammalian selection cassette expressing an EGFP 
gene was constructed as described previously (Urschitz et al., 2010). 
 
Figure 3-S2: IgTrkB is constitutively active in NCM-1 cells 
The IgTrkB construct was cloned into a piggyBAC transposon-transposase vector.  
NCM-1 cells were then stably transfected with this construct by hygromycin selection. 
IgTrkB is constituitively active in the piggyBAC vector (p < 0.01, Student’s t-test, n=3, 





Figure 3-S3: Proliferation in NCM-1 cell lines   
IgTrkB and WT NCM-1 cells, plus 5 additional NCM-1 cell lines stably transfected 
with IgTrkB were grown in culture.  All IgTrkB transfected cell lines have enhanced 
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proliferation shown by enhanced Calcein AM fluorescence compared to wild type cells 







Figure 3-S4: Cyclin D1 protein is upregulated in IgTrkB NCM-1 cells   
(a) Western blot of cyclin D1 protein in IgTrkB NCM-1 cells and wild type NCM-1 
cells.  (b) Quantification of cyclin D1 protein expression reveals a significant 6-fold 
upregulation of cyclin D1 protein in IgTrkB NCM-1 cells (p < 0.01, Student’s t-test, 




CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 
The experiments presented in this dissertation have aimed to better understand 
some of the factors that influence the phenotype of biologically unfavorable 
neuroblastoma.  We identified ciliary neurotrophic factor signaling to promote 
differentiation in MYCN amplified tumors, as well as implicated TrkB signaling as 
possibly being sufficient to give rise to neuroblastoma from developing neural crest 
precursors.  We found that the efficacy of CNTF as an in vivo treatment to reduce growth 
of MYCN amplified NHO1S subcutaneous tumors was limited.  Due to concerns of 
weight loss resulting from intraperitoneal CNTF treatment, animals received only one 
week of CNTF treatment.  Follow-up studies administering CNTF treatment every other 
day, and following tumor growth for up to two weeks may result in a more significant 
effect on NHO1S tumor growth.  Additionally, the use of the newly engineered TAT-
CNTF fusion protein (Rezende et al., 2009), which does not have the anorexic side 
effects of CNTF, would allow for greater flexibility in dosing schedules, assuming that 
this fusion protein would have similar differentiating effects in vitro.  
 
We reported that TrkB signaling is sufficient to transform the neural crest 
derived cell line NCM-1, suggesting that abberrant TrkB signaling alone may be 
sufficient to initiate tumor formation in neuroblastoma.  To formally confirm this 
hypothesis, the development of a transgenic mouse will be necessary.  Using the IgTrkB 
construct presented in this dissertation, a transgenic mouse expressing this construct 
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targeted to the neural crest lineage by the tyrosine hyrdoxylase (TH) promoter, as in the 
TH-MYCN mouse, would help to determine if TrkB signaling can be a driver of 
neuroblatoma tumor formation.  Furthermore, the utilization of an inducible promoter, 
such as an rtTA / TRE tet-On system, would allow the determination of a critical period 
for tumorigenesis, or whether or not tumor formation at different points in development 
results in different tumor cell phenotypes. 
 
TrkB and ALK – Different Means to the Same End? 
It was recently discovered that mutations in ALK, a gene coding for another tyrosine 
kinase receptor, were found to be present in the majority of familial cases of 
neuroblastoma (Mosse et al., 2008), as well as 5-15% of sporadic cases (Chen et al., 
2008).  Like TrkB, gain of function ALK mutations signal through the MAPK and AKT 
pathways.  In these ALK expressing tumors, constitutively active ALK forms a complex 
with hyperphosphorylated ShcC, rendering cells unresponsive to MAPK activating 
growth factors such as NGF (Miyake et al., 2002).  Furthermore, inhibition of ALK 
binding to ShcC results in apoptosis in mutant ALK expressing neuroblastoma cells 
(Osajima-Hakomori et al., 2005).  Like ALK, TrkB also binds ShcC (Liu and Meakin, 
2002).  Interestingly, mutations rendering ALK consitutively active are not necessary for 
the protein to have oncogenic activity in neuroblastoma.  Overexpression of the wild type 
(WT) receptor to a critical threshold level leads to constitutive phosphorylation / 
activation irrespective of whether cells harbor the mutated or WT receptor (Passoni et al., 
2009).  Furthermore, primary tumors with elevated WT ALK expression have similar 
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clinical and molecular phenotypes as tumors with activating point mutations (Schulte et 
al., 2011). 
 
Is it possible that the oncogenic properties of ALK and TrkB are mediated by the same 
mechanism?  Both of these tyrosine kinases require high levels of activation of their 
receptors, either by overexpression / activating mutations (ALK), or simultaneous 
expression of receptor and ligand (TrkB).  Furthermore, these receptors activate the same 
downstream intracellular pathways in neuroblastoma, utilizing the same ShcC adapter 
protein.  It would be interesting to determine if disruption of TrkB binding to ShcC would 
promote apoptosis in TrkB / BDNF-expressing neuroblastoma cells, as in tumor cells 
with elevated ALK activation.  If so, this might provide a common therapeutic target for 
biologically unfavorable tumor cells harboring these derangements.  Alternatively, both 
ALK and TrkB signaling converge on the mammalian target of rapamycin (mTOR) 
pathway, and mTOR inhibition might reduce the malignant phenotype of both TrkB 
(Nakamura et al., 2006) and ALK (Berry et al., 2012) expressing neuroblasotma cells.  
Therefore, the further development of mTOR inhibitors as therapeutics in neuroblastoma 
will likely have broad efficacy across tumors expressing either TrkB, and mutated or 
elevated levels of ALK.  The mTOR inhibitor temsirolimus is currently in phase II 
clinical trials for refractory neuroblastoma (Geoerger et al., 2012). 
 
 
CNTF and TrkB Signaling as Personalized Medicine? 
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Ultimately, the experiments presented here will not be applicable to all patients with 
neuroblastoma.  However, as the ability and ease of detection of molecular markers and 
genomic signatures is ever increasing, cancer treatments are becoming more and more 
personalized to individual patients (Awada et al., 2012).  Therefore, in patients who have 
failed conventional treatments, yet express the CNTFRa receptor in their tumors, 
activation of this signaling pathway might be a legitimate alternative therapeutic option to 
promote the differentiation of tumor cells.   
 
Furthermore, the sufficiency of TrkB signaling alone to transform neural crest-
derived cells strengthens the argument for targeted therapies designed to inhibit TrkB 
signaling in TrkB / BDNF-expressing neuroblastomas.  Lestaurtinib (CEP-701) is a 
tyrosine kinase inhibitor that has shown potential efficacy in phase I clinical trials for 
neuroblastoma .  Lestaurtinib inhibits Trk activation by ligand at nanomolar 
concentrations, and preclinical studies suggest it may be most effective in combination 
with conventional chemotherapeutic agents where it renders cells more susceptible to 
cytotoxic drugs (Evans, Kisselbach et al. 2001; Ho, Eggert et al. 2002).  Encouragingly, 
dose-limiting toxicities from Lestaurtinib treatment seem to be limited to nausea, 
gastrointestinal irritation, and dyspepsia, which are fairly well tolerated (Marshall, 
Kindler et al. 2005).  It will be interesting to monitor the progress of this drug through 
clinical trials, as therapies specifically targeting the derangements of high risk 
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APPENDIX A: Expression of the 5 nicotinic acetylcholine receptor subunit in 
neuroblastoma 
 
Despite surgery and chemotherapy, outcomes in high risk neuroblastoma remain 
poor (De Bernardi, Nicolas et al. 2003).  Many of these patients will initially respond to 
chemotherapy, but inevitably relapse.  One possibility for these outcomes is the presence 
of a cancer stem cell in the bone marrow that, after surviving chemotherapy treatment, is 
able to reseed the body and initiate new tumor development.  Such ‘tumor initiating cells’ 
or TICs, have been isolated from the bone marrow of relapsed neuroblastoma patients 
(Hansford, McKee et al. 2007).  Therefore, in order to prevent relapse in high risk 
neuroblastoma, new therapeutics must be developed which target these tumor initiating 
cells.   
 
 In an effort to identify compounds with the ability to kill TICs, but not normal 
cells, the lab of Dr. Kaplan at the Hospital for Sick Children in Toronto, Canada 
performed a candidate drug screen (Smith, Datti et al. 2010).  This screen identified the 
drug MG 624, a nicotinic acetylcholine receptor antagonist, to kill TICs, but not normal 
skin-derived neural crest precursor cells (SKPs) (Fig. A-1, unpublished data).  Therefore, 
we became interested in identifying what nicotinic acetylcholine receptor subunits may 
be expressed in neuroblastoma TICs, and whether this subunit expression contributes to 
the tumorigenic phenotype of these cells.   
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 To determine nicotinic acetylcholine receptor (CHRN) subunit expression in 
TICs, I isolated total RNA from one TIC line from the lab of Dr. Kaplan (NB12), and 
from one TIC line isolated by Dr. Giselle Sholler (BO11SC).  RNA was converted to 
cDNA and I performed quantitative PCR for the CHRN subunits 3 (CHRNA3), 4 
(CHRNA4), 5 (CHRNA5), 7 (CHRNA7), 2 (CHRNB2), and 4 (CHRNB4).  
Expression was compared to RNA isolated from a normal pediatric sympathetic ganglion 
(Fig. A-2).  While CHRNA3, CHRNA4, and CHRNB4 are not expressed in the TIC 
lines, interestingly, CHRNA5 is highly upregulated in the TIC lines compared with 
normal sympathetic control.  CHRNA7 and CHRNB2 are expressed in the TIC lines, but 
at relatively low levels compared with control.  Therefore, we reasoned CHRNA5 
expression may be important in the ability of MG624 to kill TICs. 
 
To determine if the observed upregulation of CHRNA5 would be consistent with other 
TIC lines, as well as compared to other controls, such as the normal skin derived neural 
crest precursor cells (SKPs) used in the candidate drug screen, Dr. Kaplan and Dr. Miller 
generously provided us with RNA isolated from a number of different TIC and SKP 
lines.  The same quantitative PCR was performed, and consistent with the first TIC lines, 
CHRNA5 is highly upregulated in all TIC lines tested (purple bars) compared with both 
SKP lines (aqua bars), and the normal sympathetic tissue control (yellow bar) (Figure A-
3).  Furthermore, as in the first TIC lines, CHRNA3, CHRNA4, and CHRNB4 are not 
expressed, while CHRNA7 and CHRNB2 are lowly expressed in all TIC lines.         
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Next we examined whether upregulation of CHRNA5 was a characteristic specific to 
neuroblastoma TICs, or whether CHRNA5 is highly expressed in established 
neuroblastoma cell lines as well.  RNA was isolated from two MYCN-amplified (KCN 
and KCNR) and one single-copy MYCN (SY5Y) neuroblastoma cell lines, and mRNA 
transcript levels were determined for CHRNA5 and CHRNA7 by quantitative PCR (Fig. 
A-4).  As in the TICs, CHRNA5 is highly upregulated in all three neuroblastoma cell 
lines tested compared with normal sympathetic control, indicating CHRNA5 
overexpression is not exclusive to neuroblastoma tumor initiating cells.  CHRNA7 was 
also expressed in the neuroblastoma cell lines.  However, unlike in the TICs, where 
CHRNA7 expression was well below that of the sympathetic control, CHRNA7 
expression levels in the neuroblastoma cell lines were equivalent to levels in the 
sympathetic control tissue.   
 
We observed upregulation of CHRNA5 in both neuroblastoma tumor initiating cells, and 
in established neuroblastoma cell lines.  However, both of these groups of cells are grown 
in culture, and therefore do not reveal whether or not CHRNA5 is upregulated in vivo.  
To determine if CHRNA5 is overexpressed in the tumors of neuroblastoma patients in 
vivo, RNA from a number of patient’s tumors was generously provided by the Children 
Oncology Group (COG).  This RNA was converted to cDNA and CHRNA5 transcript 
levels were determined by quantitative PCR as above.  Consistent with expression in both 
the TICs, and established neuroblastoma cells, CHRNA5 was upregulated in every tumor 
sample tested, up to 400-fold, compared with normal sympathetic tissue (Fig. A-5).   
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This data provides evidence that the nicotinic acetylcholine receptor subunit 5 is 
upregulated in both tumor initiating cells of neuroblastoma, and neuroblastoma patient 
tumors.  Additionally, high expression of CHRNA5 also correlates with poor patient 
survival (http://home.ccr.cancer.gov/oncology/oncogenomics/).  Interestingly, the 5 
subunit itself is unable to form a functional nicotinic acetylcholine receptor, requiring the 
presence of another alpha, and a beta subunit to be functionally active.  However, in 
addition to CHRNA5 overexpression, the TIC lines express, albeit at significantly lower 
levels, both CHRNA7 and CHRNB2, which together, can form a rarely expressed 
572 nicotinic acetylcholine receptor (Girod, Crabtree et al. 1999).  Future studies will 
need to confirm upregulation of the 5 subunit at the protein level.  Furthermore, to 
determine if CHRNA5 overexpression is physiologically relevant in neuroblastoma cells, 
or can be transforming in normal cells, RNAi knockdown of the gene should be 
performed, as well as overexpression of the gene in non-transformed cell lines.  
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Figure A-1: MG 624 kills neuroblastoma TICs, but not skin-derived neural crest 
precursors 
MG 624 reduces the growth rate of and/or kills neuroblastoma tumor initiating cells 
(TICs, yellow bars), but promotes the growth of normal skin-derived precursors (SKPs, 
blue bars) that are neural crest stem cells.  The EC50 for this effect is approximately 100 











































Figure A-2: Nicotinic acetylcholine receptor (CHRN) subunit expression in 
neuroblastoma tumor intiating cells (TICs) compared with normal sympathetic 
tissue 
Transcript levels of the nicotinic acetylcholine receptor subunits 3, 4, 5, 7, 2, and 
4 were quantified by qPCR using FAM/BHQ labeled Taqman based probes (ABI) 
relative to human 18s (house keeping gene).  CHRNA5 is highly upregulated in the two 
TIC lines compared with normal sympathetic tissue, while CHRNA3, CHRNA4, and 
CHRNB4 expression is undetectable.  CHRNA7 and CHRNB2 is lowly expressed in the 




Figure A-3: CHRNA5 is upregulated in TICs compared with skin derived stem cells 
and normal sympathetic tissue  
Total RNA from four independently isolated tumor initiating cell lines from the bone 
marrow of neuroblastoma patients (purple bars), three neural crest precursor cell lines 
from human skin follicles (aqua bars), and normal sympathetic ganglia obtained from a 
non-cancerous pediatric case at autopsy (yellow bar) were reverse transcribed into cDNA. 
CHRNA3, CHRNA4, CHRNA5, CHRNA7, CHRNB2, and CHRNB4 transcript levels 
were quantified by qPCR relative to human 18S using FAM/BHQ labeled Taqman based 
probes (ABI).  As in the previous TIC lines tested, CHRNA3, CHRNA4, and CHRNB4 
were undetectable.  CHRNA5 was upregulated 5-40 fold compared with normal 








Figure A-4: CHRNA5 is upregulated in established human neuroblastoma cell lines 
compared with normal sympathetic tissue 
Transcript levels of CHRNA5 and CHRNA7 in neuroblastoma cell lines were quantified 
by qPCR using FAM/BHQ labeled Taqman based probes (ABI) relative to human 18s 
(house keeping gene).  Consistent with CHRN expression in the TIC lines, CHRNA5 is 
highly upregulated in the established neuroblastoma cell lines SY5Y, KCN, and KCN-R 
compared with normal sympathetic tissue.  Unlike in the TICs, CHRNA7 expression in 











Figure A-5: CHRNA5 is highly expressed in patient tumor samples compared with 
normal sympathetic tissue 
Transcript levels of CHRNA5 in neuroblastoma tumor samples were quantified by qPCR 
using FAM/BHQ labeled Taqman based probes (ABI) relative to human 18s (house 
keeping gene).  Transcript levels of CHRNA5 in all tumor samples run together (blue 
bars) and a select number of tumor samples run at the same time as cDNA from normal 
sympathetic tissue (red bars).  All transcript values are expressed as fold expression 
relative to CHRNA5 expression in normal sympathetic tissue.  Samples are ordered from 
highest to lowest fold expression from left to right on the x-axis.  CHRNA5 mRNA 
expression is higher in all tumor samples compared with normal sympathetic tissue.  
Tumor sample RNA was graciously provided by the Children’s Oncology Group (COG).   
 
